

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Extubation CPAP Level Assessment Trial (ÉCLAT): In extremely preterm infants <28 weeks' gestation, undergoing their first extubation, does extubation to a higher CPAP pressure (10 cm H₂O, range 9-11 cm H₂O), compared with a standard CPAP pressure (7 cm H₂O, range 6-8 cm H₂O) decrease extubation failure within seven days?

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-045897
Article Type:	Protocol
Date Submitted by the Author:	25-Nov-2020
Complete List of Authors:	Kidman, Anna; The University of Melbourne Faculty of Medicine Dentistry and Health Sciences, Obstetrics and Gynaecology Manley, Brett; The Royal Women's Hospital, Newborn Research Centre Boland, Rosemarie Anne; Murdoch Childrens Research Institute Malhotra, Atul; Monash University, Donath, Susan; Murdoch Childrens Research Institute, Clinical Epidemiology and Biostatistics Unit Davis, Peter; The Royal Women's Hospital, Newborn Research Bhatia, Risha; Monash Children's Hospital
Keywords:	Neonatal intensive & critical care < INTENSIVE & CRITICAL CARE, NEONATOLOGY, RESPIRATORY MEDICINE (see Thoracic Medicine)

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Title Page

Title:

Extubation CPAP Level Assessment Trial (ÉCLAT): In extremely preterm infants born <28 weeks' gestation, undergoing their first extubation, does extubation to a higher CPAP pressure (10 cm H₂O, range 9-11 cm H₂O), compared with a standard CPAP pressure (7 cm H₂O, range 6-8 cm H₂O) decrease extubation failure within seven days?

Authors

[Kidman, A.M.](#)¹⁻³, Manley, B.J.^{1,2,4}, Boland, R.A.^{2,4}, Malhotra, A.^{3,5,6}, Donath, S.⁴, Davis, P.G.^{1,2,4}, and Bhatia, R.^{3,5}.

Affiliations:

1. Royal Women's Hospital, Melbourne, Australia
2. The University of Melbourne, Melbourne, Australia
3. Monash Newborn, Monash Children's Hospital, Melbourne, Australia
4. Murdoch Children's Research Institute, Melbourne, Australia
5. Department of Paediatrics, Monash University, Melbourne, Australia
6. The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Australia

Contact Details:

akidman@student.unimelb.edu.au
Brett.Manley@thewomens.org.au
rosemarie.boland@unimelb.edu.au
atul.malhotra@monash.edu
Susan.Donath@mcri.edu.au
pgd@unimelb.edu.au
Risha.Bhatia@monashhealth.org

Trial Registration

Australia and New Zealand Clinical Trial Registry: ACTRN12618001638224

Keywords:

Extremely preterm, infant, endotracheal extubation, continuous positive airway pressure.

Data sharing statement:

The protocol will be published and publicly available, and the de-identified individual patient datasets and statistical codes will be available on reasonable request.

Word count: 2604

Abstract

1
2
3 **Introduction:** Respiratory distress syndrome (RDS) is a common complication of prematurity
4 and extremely preterm infants born before 28 weeks' gestation often require endotracheal
5 intubation and mechanical ventilation. In this high-risk population, mechanical ventilation is
6 associated with lung injury and contributes to bronchopulmonary dysplasia (1). Therefore,
7 clinicians attempt to extubate infants as quickly as possible and use non-invasive respiratory
8 support such as nasal continuous positive airway pressure (CPAP) to facilitate the transition.
9 However, approximately 60% of extremely preterm infants experience 'extubation failure' and
10 require re-intubation (2). Whilst CPAP pressures of 5-8 cm H₂O are commonly used after
11 extubation, the optimal CPAP pressure is unknown (3), and higher pressures may be beneficial
12 in avoiding extubation failure.
13
14
15
16
17
18
19
20
21

22 **Methods and analysis:** A total of 200 infants born extremely preterm will be recruited prior
23 to their first attempted extubation from mechanical ventilation to CPAP. Infants will be
24 randomly assigned to one of two set CPAP pressures: CPAP 10 cm H₂O (intervention) or CPAP
25 7 cm H₂O (control). The primary outcome will be extubation failure (re-intubation) within
26 seven days.
27
28
29
30
31

32 **Ethics and dissemination:** Ethics approval has been granted by the Monash Health and Royal
33 Women's Hospital (Melbourne, Australia) Human Research Ethics Committees. Any
34 amendments to the trial protocol will be submitted to the ethics committees for approval. The
35 trial is currently recruiting at these two sites. The findings of this study will be disseminated
36 via peer-reviewed journals and presented at national and international conferences. This trial
37 was prospectively registered with Australia and New Zealand Clinical Trial Registry
38 (ACTRN12618001638224).
39
40
41
42
43
44

45 **Article Summary**

46 **Strengths and limitations of this study:**

- 47 • Strength: Randomised controlled trial
- 48 • Strength: The largest trial comparing CPAP pressure ranges to reduce extubation failure
- 49 in extremely preterm infants
- 50 • Strength: CPAP pressures as high as 9-11 cm H₂O are yet to be formally evaluated
- 51 • Strength: Multicentre trial
- 52 • Limitation: Unable to be blinded

53 **Introduction**

1
2
3 Respiratory distress syndrome (RDS) is common in preterm infants, and almost universal in
4 extremely preterm infants born <28 weeks' gestation. In this high-risk population,
5 bronchopulmonary dysplasia (BPD), the chronic lung disease of prematurity, is a major
6 morbidity following RDS and its treatment (4). Many extremely preterm infants require
7 endotracheal intubation and mechanical ventilation (4). Mechanical ventilation, particularly if
8 prolonged, injures the lungs and contributes to BPD (5). Consequently, avoiding or minimising
9 the time that extremely preterm infants are mechanically ventilated is critical.

15 The optimal way to provide respiratory support to extremely preterm infants after
16 mechanical ventilation remains under investigation, and the transition from mechanical
17 ventilation to non-invasive respiratory support remains a poorly understood process (5). There
18 is a paucity of data on the optimal timing of extubation, criteria for readiness for extubation,
19 and the best strategy to use when providing post-extubation respiratory support (6). The
20 extubation failure rate in extremely preterm infants is high, estimated at 60% (2), and reducing
21 this outcome must be a focus of research.

27 Nasal continuous positive airway pressure (CPAP) is the most frequently used mode of
28 non-invasive support used after extubation of extremely preterm infants. The reasons for
29 extubation failure during CPAP are multifactorial. Variables such as infant weight (birth weight
30 <750g), immaturity (<26 weeks' gestation) and the severity of RDS (alveolar-arterial gradient
31 >180 mm Hg) are weakly predictive of early CPAP failure in very preterm infants (2). The use
32 of a set CPAP pressure sufficient to maintain functional residual capacity is likely to be
33 important (7). The optimal CPAP pressure to use after extubation is unknown, although a meta-
34 analysis of studies suggests that pressures of at least 5 cm H₂O are needed (7). Many infants
35 are re-intubated following extubation for increased oxygen requirement and work of breathing
36 suggesting that a low end-expiratory lung volume may contribute to extubation failure (8).

45 Utilising higher CPAP pressures post-extubation may prevent alveolar collapse,
46 improve lung function and reduce extubation failure (9,10). Kitsommart *et al* compared CPAP
47 7-9 cm H₂O with CPAP 4-6 cm H₂O after extubation of infants with birth weight <1250 g and
48 demonstrated no difference in extubation failure within 72 hours (9). In a second trial, Buzzella
49 *et al* randomised very preterm infants born 23-30 weeks' gestation with RDS to receive either
50 CPAP 7-9 cm H₂O or CPAP 4-6 cm H₂O after extubation (10). Rates of extubation failure
51 within 96 hours were significantly lower in the group randomised to the higher range of CPAP
52 pressures (10). Current CPAP pressure recommendations are wide and varied (7). Most
53
54
55
56
57
58
59
60

1
2
3 clinicians report pressures of 5-8 cm H₂O however, use of CPAP pressures up to 12 cm H₂O
4 have been reported and have not been associated with adverse effects (3).
5

6
7 In extremely preterm infants, extubation failure is associated with significant
8 morbidities, including BPD, pulmonary vascular disease, airway trauma, poor feeding and oral
9 aversion, adverse neurodevelopmental outcomes, and delayed family unit bonding (11). Thus,
10 improving rates of successful extubation in this high-risk population of preterm infants is a
11 clinical priority (1,11–14). The ÉCLAT trial will investigate the CPAP pressure range of 6-8
12 cm H₂O, routinely used in our clinical practice, with a higher-pressure range of 9-11 cm H₂O.
13 We hypothesise that the higher-pressure range will result in less atelectatic pulmonary failure
14 and extubation failure.
15
16
17
18
19
20
21

22 **Methods and analysis**

23 **Study design and aim**

24 We used the APIRIT checklist when writing our report (15). This is a multicentre, unblinded,
25 randomised controlled trial. The aim of the ECLAT study is to determine, in extremely preterm
26 infants born <28 weeks' gestation who are undergoing their first extubation, whether
27 extubation to a higher CPAP pressure (10 cm H₂O, range 9-11 cm H₂O), compared with a
28 standard CPAP pressure (7 cm H₂O, range 6-8 cm H₂O) decreases extubation failure within
29 seven days.
30
31
32
33
34
35

36 **Sample size**

37 The rates of extubation failure within 7 days in extremely preterm infants at the participating
38 centres is estimated at 55%. To detect a reduction in extubation failure from 55% to 35%
39 (absolute risk reduction 20%, relative risk reduction 40%) with 80% power and a two-tailed
40 alpha error of 0.05, a sample size of 93 infants in each arm (total 186 infants) is required.
41
42
43
44

45 **Patient population**

46 Infants born extremely preterm (<28 weeks' gestation) who are intubated and
47 mechanically ventilated and being extubated for the first time are eligible for participation in
48 the ÉCLAT trial. The timing of the extubation is determined by the clinical team caring for the
49 infant, and there is no postnatal age limit for participation.
50
51
52
53
54

55 **Inclusion criteria**

56 Infants are eligible if they:

- 57 • were born <28 completed weeks' gestation
- 58
59
60

- are being extubated for the first time from mechanical ventilation to nasal CPAP
- have received enteral or intravenous caffeine (as prophylaxis for apnoea of prematurity) <24 hours prior to the planned extubation
- have received exogenous surfactant treatment.

Exclusion criteria

Infants are excluded if they:

- are being extubated to any other mode of non-invasive respiratory support other than nasal CPAP, or to no respiratory support
- have a major congenital anomaly or condition that might adversely affect breathing or ventilation: e.g. known upper airway obstruction or major airway abnormality, or major congenital heart disease
- are not receiving full intensive care after extubation.

Randomisation

Enrolled infants are randomised using REDCap electronic data capture tools (16), hosted at the Murdoch Children's Research Institute, Melbourne, Australia. REDCap (Research Electronic Data Capture) is a secure, password encrypted, web-based application designed to support data capture and randomisation for research studies. Only the infant's first extubation is randomised. Multiple births are randomised individually. Randomisation occurs after the clinical decision to extubate has been made and shortly before extubation using a computer or smartphone. Stratification is by centre and gestational age at birth (<26 weeks; ≥ 26 weeks).

Clinical Management [Figure one]

Higher CPAP pressure (Intervention)

Infants are extubated to a set CPAP pressure of **10 cm H₂O**. Whilst receiving CPAP, infants will remain within a set CPAP pressure range of **9 cm H₂O – 11 cm H₂O** for at least **24 hours**, with changes within this range at the discretion of the treating team. After 24 hours, infants may have their set CPAP pressure weaned at the discretion of the treating team but must remain within a set CPAP pressure range **5 cm H₂O – 11 cm H₂O** for at least **7 days** after extubation if receiving CPAP. Infants are re-intubated if they satisfy the extubation failure criteria

1
2
3 described below within 7 days after extubation. The fraction of inspired oxygen (FiO₂) is
4 titrated to keep oxygen saturations (SpO₂) in the standard target ranges of the participating
5 unit. If extubation failure occurs, management following re-intubation will be at the discretion
6 of the treating team. For subsequent extubations, clinicians will be encouraged to use the
7 assigned set CPAP pressure range (see figure one).
8
9
10
11
12

13 **Standard CPAP pressure (control)**

14
15 Infants are extubated to a set CPAP pressure of **7 cm H₂O**. Whilst receiving CPAP, infants will
16 remain within a set CPAP pressure range of **6 cm H₂O – 8 cm H₂O** for at least **24 hours**, with
17 changes to the set CPAP pressure within this range at the discretion of the treating team. After
18 24 hours, infants may have their set CPAP pressure weaned at the discretion of the treating
19 team but must remain within a set CPAP pressure range **5 cm H₂O – 8 cm H₂O** for at least **7**
20 **days** after extubation if receiving CPAP. Infants are re-intubated if they satisfy the extubation
21 failure criteria described below within 7 days after extubation. The FiO₂ is titrated to keep SpO₂
22 in the standard target ranges of the participating unit. If extubation failure occurs, management
23 following re-intubation will be at the discretion of the treating team. For subsequent
24 extubations, clinicians will be encouraged to use the assigned set CPAP pressure range (see
25 figure one).
26
27
28
29
30
31
32
33
34
35
36

37 **Device**

38 In both groups, infants will be extubated to continuous-flow nasal CPAP, via a mechanical
39 ventilator (either the Dräger VN500, Dräger Medical, Lübeck, Germany, or the SLE 5000,
40 SLE, Croydon, UK) operating in CPAP mode. After 24 hours the infant may be transitioned to
41 ‘bubble’ nasal CPAP (Fisher & Paykel bubble CPAP circuit, Fisher & Paykel Healthcare,
42 Auckland, New Zealand) but only if receiving a CPAP ≤ 10cmH₂O given the pressure
43 limitations of the ‘bubble’ CPAP device. Nasal CPAP may be delivered via any binasal CPAP
44 prongs or mask, according to the participating unit’s protocol.
45
46
47
48
49
50

51 **Outcomes**

52 **Extubation Failure**

53 The primary outcome is extubation failure within 7 days, defined as receiving the *maximum*
54 CPAP level (11 cm H₂O in the intervention group; 8 cm H₂O in the control group) and having
55 at least one of:
56
57
58
59
60

- FiO_2 requirement >0.20 above the pre-extubation FiO_2
- Two or more apnoeic episodes within any 24-hour period requiring intermittent positive pressure ventilation, or six or more apnoeic events requiring stimulation in any 6-hour period
- Respiratory acidosis with $\text{pH} <7.2$ and $\text{pCO}_2 >60$ mm Hg
- Require urgent intubation for an acute deterioration (at clinical discretion) with the reason for re-intubation documented.

Treatment failure

Should infants not be immediately reintubated and instead managed with non-invasive positive pressure ventilation or escalated to a higher CPAP pressure than their assigned range they will be documented as an extubation failure and reported as a protocol violation.

Secondary outcomes

- Incidence of re-intubation within 72 hours, and within 96 hours
- Incidence of
 - Failure in hours after extubation
 - Reason(s) for extubation failure
 - Kaplan Meier Survival curve between both groups
- Death before hospital discharge
- Duration of mechanical ventilation in days after randomisation in survivors
- Total duration of hospitalisation in days in survivors
- Postmenstrual age at last supplemental oxygen, and at last positive pressure ventilation (mechanical ventilation, CPAP [or variants], or nasal high-flow ≥ 2 Litres per minute) in survivors
- Incidence of treatment with systemic postnatal corticosteroids for lung disease after randomisation
- Incidence of new pneumothorax requiring drainage with thoracocentesis or intercostal catheter insertion after randomisation
- Incidence of new, radiologically-diagnosed pulmonary interstitial emphysema after randomisation

- Incidence of BPD, defined as a requirement for supplemental oxygen and/or respiratory support (mechanical ventilation, CPAP [or variants], or nasal high-flow ≥ 2 Litres per minute) at 36 weeks' post-menstrual age
- Incidence of necrotising enterocolitis Bell's stage 2 or above after randomisation (17)
- Incidence of spontaneous intestinal perforation after randomisation
- Incidence of retinopathy of prematurity requiring treatment with laser therapy or intra-ocular medication in one or both eyes after randomisation
- Incidence of new diagnosis of grade 3 or 4 intraventricular haemorrhage after randomisation

Other data

Data collected will include:

- Maternal and infant demographics: maternal parity, infant sex, gestational age at birth, birth weight in grams, mode of delivery, exposure to any antenatal corticosteroids, duration of ruptured membranes prior to delivery in days, presence of histologically diagnosed chorioamnionitis
- Postnatal age at extubation in days, last weight prior to extubation in grams, age at first intubation in hours
- Previous dose of exogenous surfactant received in milligrams/kilogram, prior treatment for a patent ductus arteriosus (pharmacological or surgical), prior systemic postnatal corticosteroids for lung disease
- Mechanical ventilator settings immediately prior to extubation (mode, mean airway pressure in mmHg, FiO_2 , tidal volumes (set and achieved), peak pressures (set and achieved) and end expiratory pressure.
- Blood gas analysis results within 24 hours prior to extubation (if applicable): lowest pH, highest pCO_2 , lowest base excess.

Data analysis plan

Statistical analysis will follow standard methods for randomised trials. For the primary outcome, the analysis will be by intention to treat and be adjusted for the pre-randomisation strata (GA and centre). For dichotomous outcomes, including the primary outcome, the two treatment groups will be compared using risk difference with 95% CI, both overall, and within the pre-specified subgroups (gestational age at birth < 26 weeks, ≥ 26 weeks). For dichotomous

1
2
3 secondary outcomes, analysis will be limited to the two treatment groups, using risk difference
4 with 95% CI. For continuous outcomes, the two treatment groups will be compared using
5 difference of means, together with 95% CI, for outcome variables which are normally
6 distributed; for outcome variables, which are not normally distributed, the comparison will be
7 difference of medians, with 95% CI. All comparisons (risk difference, difference of means,
8 difference of medians) will be estimated using regression models with the randomisation strata
9 as covariates, and with standard errors adjusted to take into account the clustering due to
10 multiple births. Reporting of findings will be done in accordance with CONSORT guidelines.

17 **Ethics and Dissemination**

18
19 Infants are only enrolled after prospective, informed, written parental consent. Parent(s)
20 of eligible infants will be approached by a member of the research team. A verbal explanation
21 of the study and a Parent Information and Consent Form will be provided. Where the parents
22 of an eligible infant do not speak English sufficient to give informed consent, interpreters will
23 be used to assist with the consent process.

24
25 The ÉCLAT study has received ethics approval from the Human Research Ethics
26 Committees of The Royal Women's Hospital, Melbourne, Australia and Monash Health,
27 Melbourne, Australia.

34 **Patient and public involvement**

35
36 Both human research and ethics committees at each recruitment centre have consumer input
37 before trial approval to determine suitability of study design and consent forms.

39 **Adverse events**

40
41 Adverse events (AEs) are recorded within 7 days after the randomised extubation. They
42 are recorded as part of the study design and secondary outcomes of ÉCLAT. The site
43 investigators are responsible for recording all AEs regardless of their relationship to the
44 intervention. The following outcome are designated as AEs:

- 45 • Necrotising enterocolitis (Bell's stage III or IV) (17)
- 46 • Intraventricular haemorrhage (grade III or IV)

53 **Serious adverse events**

54
55 Serious adverse events (SAEs) are recorded within 7 days after the randomised
56 extubation. All are prespecified secondary outcomes of ÉCLAT. The investigators are
57 responsible for recording all events regardless of their relationship to the intervention. All
58
59
60

1
2
3 SAE's are reported to an independent Data Safety Monitoring Committee (DSMC) and the
4 local ethics committee within 72 hours of the principle investigator being notified. The
5 following outcomes are designated as SAEs:
6
7

- 8 • Death
- 9
- 10 • Spontaneous intestinal perforation
- 11
- 12 • Pneumothorax
- 13
- 14 • Pulmonary interstitial emphysema
- 15

16 17 **Study Oversight**

18
19 The independent DMSC established for the ÉCLAT trial have their roles and
20 responsibilities detailed in a separate DSMC Charter. The DSMC includes two independent,
21 experienced neonatologists, and a senior statistician. The terms of reference for the DSMC
22 include performance of interim safety analyses, periodic examination of relevant emerging
23 external evidence, monitoring of adverse events, compliance with the trial protocol, and
24 progress of recruitment. Safety analyses by the DMSC are planned after the primary outcome
25 is known for the first 50 and 100 infants and will occur blinded to group allocation. If required,
26 an additional safety analysis will be performed at 150 infants. No interim analyses of the
27 primary outcome are planned.
28
29
30
31
32
33

34 35 **Clinical Significance**

36
37 Extubation failure is common in extremely preterm infants and associated with
38 important neonatal morbidities (2). CPAP is the most commonly used form of non-invasive
39 ventilation used post-extubation but the optimal pressure to use for this indication remains
40 uncertain. The ÉCLAT study will reveal novel information regarding CPAP pressures in
41 extremely preterm infants. The ÉCLAT study is the largest trial comparing and researching
42 CPAP pressures >8 cm H₂O. Results from ÉCLAT will inform clinical practice and support
43 clinicians in understanding and optimising CPAP pressures for extremely preterm infants.
44 Results from this study will be disseminated via peer-reviewed journals and presented at
45 national and international scientific conferences.
46
47
48
49
50
51
52

53 54 **Author Statement**

55
56 RB, AM and AK developed the concept and RB and AK wrote the protocol. BM, RAB,
57 AM and PD gave input into the protocol and revised the manuscript. SD designed the statistical
58
59
60

1
2
3 analysis and revised the manuscript. All authors have read and approved the final manuscript
4 and are accountable for its accuracy.
5
6
7

8 **Funding**

9
10 There are no funders to report for this submission
11
12

13 This work is unfunded and a project towards a Doctor of Philosophy degree at the University
14 of Melbourne, Australia. However, AK would like to thank the centre for research excellence
15 in Newborn Medicine for their support NHMRC, GNT 1153176.
16
17
18

19 **Competing interests**

20
21 None declared.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Thébaud B, Goss KN, Laughon M, Whitsett JA, Abman SH, Steinhorn RH, et al. Bronchopulmonary dysplasia. *Nat Rev Dis Primer*. 2019 Dec;5(1):78.
2. Gupta D, Greenberg RG, Sharma A, Natarajan G, Cotten M, Thomas R, et al. A predictive model for extubation readiness in extremely preterm infants. *J Perinatol*. 2019 Dec;39(12):1663–9.
3. Roehr CC. CPAP in Neonates: Current Methods and Further Improvements. In: Esquinas AM, Fiorentino G, Insalaco G, Mina B, Duan J, Mondardini MC, et al., editors. *Noninvasive Ventilation in Sleep Medicine and Pulmonary Critical Care: Critical Analysis of 2018-19 Clinical Trials [Internet]*. Cham: Springer International Publishing; 2020. p. 465–75. Available from: https://doi.org/10.1007/978-3-030-42998-0_51
4. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, te Pas A, et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome – 2019 Update. *Neonatology*. 2019;115(4):432–50.
5. Shalish W, Kanbar L, Kovacs L, Chawla S, Keszler M, Rao S, et al. The Impact of Time Interval between Extubation and Reintubation on Death or Bronchopulmonary Dysplasia in Extremely Preterm Infants. *J Pediatr*. 2019 Feb;205:70-76.e2.
6. Chawla S, Natarajan G, Shankaran S, Carper B, Brion LP, Keszler M, et al. Markers of Successful Extubation in Extremely Preterm Infants, and Morbidity After Failed Extubation. *J Pediatr*. 2017 Oct;189:113-119.e2.
7. Davis PG, Henderson-Smart DJ. Nasal continuous positive airways pressure immediately after extubation for preventing morbidity in preterm infants. *Cochrane Database Syst Rev*. 2003;(2):CD000143.
8. Manley BJ, Doyle LW, Owen LS, Davis PG. Extubating Extremely Preterm Infants: Predictors of Success and Outcomes following Failure. *J Pediatr*. 2016 Jun;173:45–9.
9. Kitsommart R, MHSc AK, Al-Saleem N, Rnc MJ, Sant’Anna GM. Levels of Nasal CPAP Applied During the Immediate Post- Extubation Phase: A Randomized Controlled Pilot Trial. 2013;3(1):9.
10. Buzzella B, Claire N, D’Ugard C, Bancalari E. A Randomized Controlled Trial of Two Nasal Continuous Positive Airway Pressure Levels after Extubation in Preterm Infants. *J Pediatr*. 2014 Jan;164(1):46–51.
11. Jois RS. Understanding long-term neurodevelopmental outcomes of very and extremely preterm infants: A clinical review. *Aust J Gen Pract*. 2019 Jan 1;48(1–2):26–31.
12. Thomas RE, Rao SC, Minutillo C, Vijayasekaran S, Nathan EA. Severe acquired subglottic stenosis in neonatal intensive care graduates: a case–control study. *Arch Dis Child - Fetal Neonatal Ed*. 2018 Jul;103(4):F349–54.

13. Jadcherla SR, Wang M, Vijayapal AS, Leuthner SR. Impact of prematurity and comorbidities on feeding milestones in neonates: a retrospective study. *J Perinatol*. 2010 Mar;30(3):201–8.
14. Janvier A. *Breathe, Baby, Breathe!: Neonatal Intensive Care, Prematurity, and Complicated Pregnancies*. University of Toronto Press; 2020.
15. Chan A-W, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. *BMJ*. 2013 Jan 9;346(jan08 15):e7586–e7586.
16. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009 Apr;42(2):377–81.
17. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal Necrotizing Enterocolitis: Therapeutic Decisions Based upon Clinical Staging. *Ann Surg*. 1978 Jan;187(1):1–7.


List of figures:

Figure 1: Study Procedure

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Figure 1: Study Procedure



ÉCLAT Study Procedure

146x90mm (300 x 300 DPI)

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586

	Reporting Item	Page Number
Administrative information		
Title	#1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a Trial identifier and registry name. If not yet registered, name of intended registry	1
Trial registration: data set	#2b All items from the World Health Organization Trial Registration Data Set	1
Protocol version	#3 Date and version identifier	1
Funding	#4 Sources and types of financial, material, and other support	11
Roles and responsibilities: contributorship	#5a Names, affiliations, and roles of protocol contributors	10

1	Roles and	#5b	Name and contact information for the trial sponsor	n/a no trial
2	responsibilities:			sponsor.
3	sponsor contact			investigator led
4	information			trial
5				
6				
7				
8	Roles and	#5c	Role of study sponsor and funders, if any, in study design;	n/a no trial
9	responsibilities:		collection, management, analysis, and interpretation of	sponsor.
10	sponsor and funder		data; writing of the report; and the decision to submit the	investigator led
11			report for publication, including whether they will have	trial
12			ultimate authority over any of these activities	
13				
14				
15				
16	Roles and	#5d	Composition, roles, and responsibilities of the coordinating	9-10
17	responsibilities:		centre, steering committee, endpoint adjudication	
18	committees		committee, data management team, and other individuals or	
19			groups overseeing the trial, if applicable (see Item 21a for	
20			data monitoring committee)	
21				
22				
23				
24	Introduction			
25				
26	Background and	#6a	Description of research question and justification for	3-4
27	rationale		undertaking the trial, including summary of relevant studies	
28			(published and unpublished) examining benefits and harms	
29			for each intervention	
30				
31				
32				
33	Background and	#6b	Explanation for choice of comparators	4
34	rationale: choice of			
35	comparators			
36				
37				
38	Objectives	#7	Specific objectives or hypotheses	4
39				
40				
41	Trial design	#8	Description of trial design including type of trial (eg,	4
42			parallel group, crossover, factorial, single group), allocation	
43			ratio, and framework (eg, superiority, equivalence, non-	
44			inferiority, exploratory)	
45				
46				
47				
48	Methods:			
49	Participants,			
50	interventions, and			
51	outcomes			
52				
53				
54	Study setting	#9	Description of study settings (eg, community clinic,	4
55			academic hospital) and list of countries where data will be	
56				
57				
58				
59				
60				

1		collected. Reference to where list of study sites can be	
2		obtained	
3			
4	Eligibility criteria	#10 Inclusion and exclusion criteria for participants. If	4-5
5		applicable, eligibility criteria for study centres and	
6		individuals who will perform the interventions (eg,	
7		surgeons, psychotherapists)	
8			
9			
10			
11	Interventions:	#11a Interventions for each group with sufficient detail to allow	5-7
12	description	replication, including how and when they will be	
13		administered	
14			
15			
16	Interventions:	#11b Criteria for discontinuing or modifying allocated	7
17	modifications	interventions for a given trial participant (eg, drug dose	
18		change in response to harms, participant request, or	
19		improving / worsening disease)	
20			
21			
22			
23	Interventions:	#11c Strategies to improve adherence to intervention protocols,	n/a
24	adherence	and any procedures for monitoring adherence (eg, drug	
25		tablet return; laboratory tests)	
26			
27			
28	Interventions:	#11d Relevant concomitant care and interventions that are	n/a
29	concomitant care	permitted or prohibited during the trial	
30			
31			
32	Outcomes	#12 Primary, secondary, and other outcomes, including the	7-8
33		specific measurement variable (eg, systolic blood pressure),	
34		analysis metric (eg, change from baseline, final value, time	
35		to event), method of aggregation (eg, median, proportion),	
36		and time point for each outcome. Explanation of the	
37		clinical relevance of chosen efficacy and harm outcomes is	
38		strongly recommended	
39			
40			
41			
42			
43	Participant timeline	#13 Time schedule of enrolment, interventions (including any	5
44		run-ins and washouts), assessments, and visits for	
45		participants. A schematic diagram is highly recommended	
46		(see Figure)	
47			
48			
49			
50	Sample size	#14 Estimated number of participants needed to achieve study	4
51		objectives and how it was determined, including clinical	
52		and statistical assumptions supporting any sample size	
53		calculations	
54			
55			
56			
57	Recruitment	#15 Strategies for achieving adequate participant enrolment to	4
58		reach target sample size	
59			
60			

Methods:**Assignment of interventions (for controlled trials)**

Allocation: sequence generation	#16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	5
Allocation concealment mechanism	#16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	5
Allocation: implementation	#16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	5
Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	n/a unblinded trial
Blinding (masking): emergency unblinding	#17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	n/a unblinded trial

Methods: Data collection, management, and analysis

Data collection plan	#18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	7-8
----------------------	----------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----

1	Data collection plan:	#18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	n/a no long term follow up
2	retention			
3				
4				
5				
6				
7				
8	Data management	#19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	5
9				
10				
11				
12				
13				
14				
15				
16	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	4
17				
18				
19				
20				
21	Statistics: additional analyses	#20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	4
22				
23				
24				
25	Statistics: analysis population and missing data	#20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	4
26				
27				
28				
29				
30				
31	Methods:			
32	Monitoring			
33				
34	Data monitoring: formal committee	#21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	10
35				
36				
37				
38				
39				
40				
41				
42				
43				
44	Data monitoring: interim analysis	#21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	10
45				
46				
47				
48				
49	Harms	#22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	9-10
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Auditing	#23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	10
2				
3				
4				
5				
6	Ethics and			
7	dissemination			
8				
9				
10	Research ethics approval	#24	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	9
11				
12				
13				
14	Protocol amendments	#25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	9
15				
16				
17				
18				
19				
20				
21	Consent or assent	#26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	7-8
22				
23				
24				
25				
26	Consent or assent: ancillary studies	#26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	n/a
27				
28				
29				
30				
31	Confidentiality	#27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	10
32				
33				
34				
35				
36				
37				
38	Declaration of interests	#28	Financial and other competing interests for principal investigators for the overall trial and each study site	11
39				
40				
41				
42	Data access	#29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	9
43				
44				
45				
46				
47	Ancillary and post trial care	#30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
48				
49				
50				
51				
52				
53	Dissemination policy: trial results	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	2
54				
55				
56				
57				
58				
59				

1	Dissemination policy:	#31b	Authorship eligibility guidelines and any intended use of	2
2	authorship		professional writers	
3				
4	Dissemination policy:	#31c	Plans, if any, for granting public access to the full protocol,	1
5	reproducible research		participant-level dataset, and statistical code	
6				
7				
8	Appendices			
9				
10	Informed consent	#32	Model consent form and other related documentation given	9
11	materials		to participants and authorised surrogates	
12				
13				
14	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of	n/a no
15			biological specimens for genetic or molecular analysis in	biological
16			the current trial and for future use in ancillary studies, if	specimens
17			applicable	
18				
19				
20				

Notes:

- 24 • 5b: n/a no trial sponsor. investigator led trial
- 25
- 26 • 5c: n/a no trial sponsor. investigator led trial
- 27
- 28 • 17a: n/a unblinded trial
- 29
- 30 • 17b: n/a unblinded trial
- 31
- 32
- 33 • 18b: n/a no long term follow up
- 34
- 35 • 33: n/a no biological specimens The SPIRIT checklist is distributed under the terms of the Creative
- 36 Commons Attribution License CC-BY-ND 3.0. This checklist was completed on 15. October 2020 using
- 37 <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

BMJ Open

A randomised Controlled Trial Comparing Two CPAP Levels to Prevent Extubation failure in Extremely Preterm Infants.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-045897.R1
Article Type:	Protocol
Date Submitted by the Author:	19-Apr-2021
Complete List of Authors:	Kidman, Anna; The University of Melbourne Faculty of Medicine Dentistry and Health Sciences, Obstetrics and Gynaecology ; Monash Newborn at Monash Children's Hospital, Monash Newborn Manley, Brett; The University of Melbourne Department of Obstetrics and Gynaecology; The Royal Women's Hospital, Newborn Research Centre Boland, Rosemarie Anne; The University of Melbourne Faculty of Medicine Dentistry and Health Sciences, Obstetrics and Gynaecology ; Murdoch Childrens Research Institute Malhotra, Atul; Monash Newborn at Monash Children's Hospital, Monash Newborn; Monash University, Paediatrics Donath, Susan; Murdoch Childrens Research Institute, Clinical Epidemiology and Biostatistics Unit Davis, Peter; The University of Melbourne Faculty of Medicine Dentistry and Health Sciences, Obstetrics and Gynaecology ; The Royal Women's Hospital, Newborn Research Bhatia, Risha; Monash Newborn at Monash Children's Hospital; Monash University, Paediatrics
Primary Subject Heading:	Paediatrics
Secondary Subject Heading:	Intensive care, Obstetrics and gynaecology
Keywords:	Neonatal intensive & critical care < INTENSIVE & CRITICAL CARE, NEONATOLOGY, RESPIRATORY MEDICINE (see Thoracic Medicine)

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Title Page

Title:

A randomised Controlled Trial Comparing Two CPAP Levels to Prevent Extubation failure in Extremely Preterm Infants.

Authors

* [Kidman, A.M.](#)¹⁻³, Manley, B.J.^{1,3,4}, Boland, R.A^{1,4}, Malhotra, A.^{2,5,6}, Donath, S.⁴, Davis, P.G.^{1,3,4}, and Bhatia, R^{2,5}.

Affiliations:

1. The University of Melbourne Faculty of Medicine Dentistry and Health Sciences, Obstetrics and Gynaecology Melbourne, VIC, AUS
2. Monash Newborn at Monash Children's Hospital, Monash Newborn
3. The Royal Women's Hospital, Newborn Research Centre Level 7, 20 Flemington Road Parkville, VIC, AUS
4. Murdoch Children's Research Institute, Clinical Epidemiology and Biostatistics Unit Melbourne, VIC, AUS
5. Monash University, Paediatrics Clayton, VIC, AUS
6. The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Australia

Contact Details:

* akidman@student.unimelb.edu.au

Anna Kidman

The University of Melbourne
Faculty of Medicine Dentistry and Health Sciences
Obstetrics and Gynaecology
Newborn Research
20 Flemington Road
Parkville, VIC
Australia 3052

Trial Registration

Australia and New Zealand Clinical Trial Registry: ACTRN12618001638224

Keywords:

Extremely preterm, infant, endotracheal extubation, continuous positive airway pressure.

Data sharing statement:

The protocol will be published and publicly available, and the de-identified individual patient datasets and statistical codes will be available on reasonable request.

Word count: 2604

Abstract

Introduction: Respiratory distress syndrome (RDS) is a complication of prematurity and extremely preterm infants born before 28 weeks' gestation often require endotracheal intubation and mechanical ventilation. In this high-risk population, mechanical ventilation is associated with lung injury and contributes to bronchopulmonary dysplasia. Therefore, clinicians attempt to extubate infants as quickly and use non-invasive respiratory support such as nasal continuous positive airway pressure (CPAP) to facilitate the transition. However, approximately 60% of extremely preterm infants experience 'extubation failure' and require re-intubation. Whilst CPAP pressures of 5-8cmH₂O are commonly used, the optimal CPAP pressure is unknown, and higher pressures may be beneficial in avoiding extubation failure. Our trial is the Extubation CPAP Level Assessment Trial (ÉCLAT). The aim of this trial is to compare higher CPAP pressures 9-11cmH₂O with a current standard pressures of 6-8cmH₂O on extubation failure in extremely preterm infants.

Methods and analysis: 200 extremely preterm infants will be recruited prior to their first extubation from mechanical ventilation to CPAP. This is a parallel group randomised controlled trial. Infants will be randomised to one of two set CPAP pressures: CPAP10cmH₂O (intervention) or CPAP 7cmH₂O (control). The primary outcome will be extubation failure (re-intubation) within seven-days. Statistical analysis will follow standard methods for randomised trials on an intention to treat basis. For the primary outcome, this will be by intention to treat, adjusted for the pre-randomisation strata (GA and centre). We will use the appropriate parametric and non-parametric statistical tests.

Ethics and dissemination: Ethics approval has been granted by the Monash Health Human Research Ethics Committees. Amendments to the trial protocol will be submitted for approval. The findings of this study will be disseminated via peer-reviewed journals and presented at

1
2
3 national and international conferences. This trial was prospectively registered with Australia
4 and New Zealand Clinical Trial Registry ACTRN12618001638224.
5
6
7

8 **Article Summary**

9 **Strengths and limitations of this study:**

- 10 • This study is a multicentre randomised controlled trial
- 11 • This study is the largest trial comparing CPAP pressure ranges to reduce extubation
12 failure in extremely preterm infants
- 13 • CPAP pressures as high as 9-11 cm H₂O are yet to be formally evaluated in extremely
14 preterm infants
- 15 • Due to the nature of the interventions blinding of patients and clinicians are unable to
16 occur.
17
18
19
20
21
22
23
24
25

26 **Introduction**

27 Respiratory distress syndrome (RDS) is common in preterm infants, and almost universal in
28 extremely preterm infants born <28 weeks' gestation. In this high-risk population,
29 bronchopulmonary dysplasia (BPD), the chronic lung disease of prematurity, is a major
30 morbidity following RDS and its treatment (1). Many extremely preterm infants require
31 endotracheal intubation and mechanical ventilation (1). Mechanical ventilation, particularly if
32 prolonged, injures the lungs and contributes to BPD (2). Consequently, avoiding or minimising
33 the time that extremely preterm infants are mechanically ventilated is critical.
34
35
36
37
38

39 The optimal way to provide respiratory support to extremely preterm infants after
40 mechanical ventilation remains under investigation, and the transition from mechanical
41 ventilation to non-invasive respiratory support remains a poorly understood process (2). There
42 is a paucity of data on the optimal timing of extubation, criteria for readiness for extubation,
43 and the best strategy to use when providing post-extubation respiratory support (3). The
44 extubation failure rate in extremely preterm infants is high (4), and reducing this outcome must
45 be a focus of research.
46
47
48
49
50

51 Nasal continuous positive airway pressure (CPAP) is the most frequently used mode of
52 non-invasive support used after extubation of extremely preterm infants. The reasons for
53 extubation failure during CPAP are multifactorial. Variables such as infant weight (birth weight
54 <750g), immaturity (<26 weeks' gestation) and the severity of RDS (alveolar-arterial gradient
55 >180 mm Hg) are weakly predictive of early CPAP failure in very preterm infants (5). The use
56 of a set CPAP pressure sufficient to maintain functional residual capacity is likely to be
57
58
59
60

1
2
3 important (6). The optimal CPAP pressure to use after extubation is unknown, although a meta-
4 analysis of studies suggests that pressures of at least 5 cm H₂O are needed (6). Many infants
5 are re-intubated following extubation for increased oxygen requirement and work of breathing
6 suggesting that a low end-expiratory lung volume may contribute to extubation failure (5).
7
8
9

10 Utilising higher CPAP pressures post-extubation may prevent alveolar collapse,
11 improve lung function and reduce extubation failure (7,8). Kitsommart *et al* compared CPAP
12 7-9 cm H₂O with CPAP 4-6 cm H₂O after extubation of infants with birth weight <1250 g and
13 demonstrated no difference in extubation failure within 72 hours (7). In a second trial, Buzzella
14 *et al* randomised very preterm infants born 23-30 weeks' gestation with RDS to receive either
15 CPAP 7-9 cm H₂O or CPAP 4-6 cm H₂O after extubation (8). Rates of extubation failure within
16 96 hours were significantly lower in the group randomised to the higher range of CPAP
17 pressures (8). Current CPAP pressure recommendations are wide and varied (6). Most
18 clinicians report pressures of 5-8 cm H₂O however, use of CPAP pressures up to 12 cm H₂O
19 have been reported and have not been associated with adverse effects (9).
20
21
22
23
24
25
26
27

28 In extremely preterm infants, extubation failure is associated with significant
29 morbidities, including BPD, pulmonary vascular disease, airway trauma, poor feeding and oral
30 aversion, adverse neurodevelopmental outcomes, and delayed family unit bonding (10). Thus,
31 improving rates of successful extubation in this high-risk population of preterm infants is a
32 clinical priority (10–14). The ÉCLAT trial will investigate the CPAP pressure range of 6-8 cm
33 H₂O, routinely used in our clinical practice, with a higher-pressure range of 9-11 cm H₂O. We
34 hypothesise that the higher-pressure range will result in less atelectatic pulmonary failure and
35 extubation failure.
36
37
38
39
40
41
42

43 **Methods and analysis**

44 **Study design and aim**

45 We used the SPIRIT checklist when writing our report (15). This is a multicentre, unblinded,
46 randomised controlled trial. The aim of the ÉCLAT study is to determine, in extremely preterm
47 infants born <28 weeks' gestation who are undergoing their first extubation, whether
48 extubation to a higher CPAP pressure (10 cm H₂O, range 9-11 cm H₂O), compared with a
49 standard CPAP pressure (7 cm H₂O, range 6-8 cm H₂O) decreases extubation failure within
50 seven days.
51
52
53
54
55
56

57 **Sample size**

1
2
3 The rates of extubation failure within 7 days in extremely preterm infants at the participating
4 centres is estimated at 55%. To detect a reduction in extubation failure from 55% to 35%
5 (absolute risk reduction 20%, relative risk reduction 40%) with 80% power and a two-tailed
6 alpha error of 0.05, a sample size of 93 infants in each arm (total 186 infants) is required.
7
8
9

10 **Patient population**

11 Infants born extremely preterm (<28 weeks' gestation) who are intubated and
12 mechanically ventilated and being extubated for the first time are eligible for participation in
13 the ÉCLAT trial. The timing of the extubation is determined by the clinical team caring for the
14 infant, and there is no postnatal age limit for participation.
15
16
17
18
19

20 **Inclusion criteria**

21 Infants are eligible if they:

- 22 • were born <28 completed weeks' gestation
- 23 • are being extubated for the first time from mechanical ventilation to nasal CPAP
- 24 • have received enteral or intravenous caffeine (as prophylaxis for apnoea of prematurity)
25 <24 hours prior to the planned extubation
- 26 • have received exogenous surfactant treatment.
27
28
29
30
31
32
33

34 **Exclusion criteria**

35 Infants are excluded if they:

- 36 • are being extubated to any other mode of non-invasive respiratory support other than nasal
37 CPAP, or to no respiratory support
- 38 • have a major congenital anomaly or condition that might adversely affect breathing or
39 ventilation: e.g. known upper airway obstruction or major airway abnormality, or major
40 congenital heart disease
- 41 • are not receiving full intensive care after extubation.
42
43
44
45
46
47
48
49

50 **Randomisation**

51 Enrolled infants are randomised using REDCap electronic data capture tools (16),
52 hosted at the Murdoch Children's Research Institute, Melbourne, Australia. REDCap
53 (Research Electronic Data Capture) is a secure, password encrypted, web-based application
54 designed to support data capture and randomisation for research studies. Only the infant's first
55 extubation is randomised. Multiple births are randomised individually. Randomisation occurs
56
57
58
59
60

1
2
3 after the clinical decision to extubate has been made and shortly before extubation using a
4 computer or smartphone. Stratification is by centre and gestational age at birth (<26 weeks;
5 ≥26 weeks).
6
7
8
9

10 **Clinical Management [Figure one]**

11 **Higher CPAP pressure (Intervention)**

12
13
14
15 Infants are extubated to a set CPAP pressure of **10 cm H₂O**. Whilst receiving CPAP, infants
16 will remain within a set CPAP pressure range of **9 cm H₂O – 11 cm H₂O** for at least **24 hours**,
17 with changes within this range at the discretion of the treating team. After 24 hours, infants
18 may have their set CPAP pressure weaned at the discretion of the treating team but must remain
19 within a set CPAP pressure range **5 cm H₂O – 11 cm H₂O** for at least **7 days** after extubation
20 if receiving CPAP. Infants are re-intubated if they satisfy the extubation failure criteria
21 described below within 7 days after extubation. The fraction of inspired oxygen (FiO₂) is
22 titrated to keep oxygen saturations (SpO₂) in the standard target ranges of the participating
23 unit. If extubation failure occurs, management following re-intubation will be at the discretion
24 of the treating team. For subsequent extubations, clinicians will be encouraged to use the
25 assigned set CPAP pressure range (see figure one).
26
27
28
29
30
31
32
33
34
35

36 **Standard CPAP pressure (control)**

37
38 Infants are extubated to a set CPAP pressure of **7 cm H₂O**. Whilst receiving CPAP, infants will
39 remain within a set CPAP pressure range of **6 cm H₂O – 8 cm H₂O** for at least **24 hours**, with
40 changes to the set CPAP pressure within this range at the discretion of the treating team. After
41 24 hours, infants may have their set CPAP pressure weaned at the discretion of the treating
42 team but must remain within a set CPAP pressure range **5 cm H₂O – 8 cm H₂O** for at least **7**
43 **days** after extubation if receiving CPAP. Infants are re-intubated if they satisfy the extubation
44 failure criteria described below within 7 days after extubation. The FiO₂ is titrated to keep SpO₂
45 in the standard target ranges of the participating unit. If extubation failure occurs, management
46 following re-intubation will be at the discretion of the treating team. For subsequent
47 extubations, clinicians will be encouraged to use the assigned set CPAP pressure range (see
48 figure one).
49
50
51
52
53
54
55
56
57
58
59
60

Device

1
2
3 In both groups, infants will be extubated to continuous-flow nasal CPAP, via a mechanical
4 ventilator (either the Dräger VN500, Dräger Medical, Lübeck, Germany, or the SLE 5000,
5 SLE, Croydon, UK) operating in CPAP mode. After 24 hours the infant may be transitioned to
6 ‘bubble’ nasal CPAP (Fisher & Paykel bubble CPAP circuit, Fisher & Paykel Healthcare,
7 Auckland, New Zealand) but only if receiving a CPAP $\leq 10\text{cmH}_2\text{O}$ given the pressure
8 limitations of the ‘bubble’ CPAP device. Nasal CPAP may be delivered via any binasal CPAP
9 prongs or mask, according to the participating unit’s protocol. Nasal prongs should be sized as
10 per the manufactures guidelines to the largest size to occlude the infant’s nares.
11
12
13
14
15
16
17
18

19 **Outcomes**

20 **Extubation Failure**

21 The primary outcome is extubation failure within 7 days, defined as receiving the *maximum*
22 CPAP level (11 cm H₂O in the intervention group; 8 cm H₂O in the control group) and having
23 at least one of:
24
25
26

- 27 • FiO₂ requirement >0.20 above the pre-extubation FiO₂
- 28 • Two or more apnoeic episodes within any 24-hour period requiring intermittent positive
29 pressure ventilation, or six or more apnoeic events requiring stimulation in any 6-hour
30 period
- 31 • Respiratory acidosis with pH <7.2 and pCO₂ >60 mm Hg
- 32 • Require urgent intubation for an acute deterioration (at clinical discretion) with the reason
33 for re-intubation documented.
- 34
35
36
37
38
39
40
41

42 **Treatment failure**

43 Should infants not be immediately reintubated and instead managed with non-invasive positive
44 pressure ventilation or escalated to a higher CPAP pressure than their assigned range they will
45 be documented as an extubation failure and reported as a protocol violation.
46
47
48
49

50 **Secondary outcomes**

- 51 • Incidence of re-intubation within 72 hours, and within 96 hours
- 52 • Failure in hours after extubation
 - 53 ○ Reason(s) for extubation failure
 - 54 ○ Kaplan Meier Survival curve between both groups
- 55 • Death before hospital discharge
- 56
57
58
59
60

- Duration of mechanical ventilation in days after randomisation in survivors
- Total duration of hospitalisation in days in survivors
- Postmenstrual age at last supplemental oxygen, and at last positive pressure ventilation (mechanical ventilation, CPAP [or variants], or nasal high-flow >2 Litres per minute) in survivors
- Incidence of treatment with systemic postnatal corticosteroids for lung disease after randomisation
- Incidence of new pneumothorax requiring drainage with thoracocentesis or intercostal catheter insertion after randomisation
- Incidence of new, radiologically-diagnosed pulmonary interstitial emphysema after randomisation
- Incidence of BPD, defined as a requirement for supplemental oxygen and/or respiratory support (mechanical ventilation, CPAP [or variants], or nasal high-flow >2 Litres per minute) at 36 weeks' post-menstrual age
- Incidence of necrotising enterocolitis Bell's stage 2 or above after randomisation (17)
- Incidence of spontaneous intestinal perforation after randomisation
- Incidence of retinopathy of prematurity requiring treatment with laser therapy or intra-ocular medication in one or both eyes after randomisation
- Incidence of new diagnosis of grade 3 or 4 intraventricular haemorrhage after randomisation

Other data

Data collected will include:

- Maternal and infant demographics: maternal parity, infant sex, gestational age at birth, birth weight in grams, mode of delivery, exposure to any antenatal corticosteroids, duration of ruptured membranes prior to delivery in days, presence of histologically diagnosed chorioamnionitis
- Postnatal age at extubation in days, last weight prior to extubation in grams, age at first intubation in hours
- Previous dose of exogenous surfactant received in milligrams/kilogram, prior treatment for a patent ductus arteriosus (pharmacological or surgical), prior systemic postnatal corticosteroids for lung disease

- Mechanical ventilator settings immediately prior to extubation (mode, mean airway pressure in mmHg, FiO₂, tidal volumes (set and achieved), peak pressures (set and achieved) and end expiratory pressure.
- Blood gas analysis results within 24 hours prior to extubation (if applicable): lowest pH, highest pCO₂, lowest base excess.

Data analysis plan

Statistical analysis will follow standard methods for randomised trials. For the primary outcome, the analysis will be by intention to treat and be adjusted for the pre-randomisation strata (GA and centre). For dichotomous outcomes, including the primary outcome, the two treatment groups will be compared using risk difference with 95% CI, both overall, and within the pre-specified subgroups (gestational age at birth <26 weeks, ≥26 weeks). For dichotomous secondary outcomes, analysis will be limited to the two treatment groups, using risk difference with 95% CI. For continuous outcomes, the two treatment groups will be compared using difference of means, together with 95% CI, for outcome variables which are normally distributed; for outcome variables, which are not normally distributed, the comparison will be difference of medians, with 95% CI. All comparisons (risk difference, difference of means, difference of medians) will be estimated using regression models with the randomisation strata as covariates, and with standard errors adjusted to take into account the clustering due to multiple births. Reporting of findings will be done in accordance with CONSORT guidelines.

Ethics and Dissemination

Infants are only enrolled after prospective, informed, written parental consent. Parent(s) of eligible infants will be approached by a member of the research team. A verbal explanation of the study and a Parent Information and Consent Form will be provided. Where the parents of an eligible infant do not speak English sufficient to give informed consent, interpreters will be used to assist with the consent process.

The ÉCLAT study has received ethics approval from the Human Research Ethics Committees of The Royal Women's Hospital, Melbourne, Australia and Monash Health, Melbourne, Australia.

Patient and public involvement

Both human research and ethics committees at each recruitment centre have consumer input before trial approval to determine suitability of study design and consent forms.

Adverse events

Adverse events (AEs) are recorded within 7 days after the randomised extubation. They are recorded as part of the study design and secondary outcomes of ÉCLAT. The site investigators are responsible for recording all AEs regardless of their relationship to the intervention. The following outcome are designated as AEs:

- Necrotising enterocolitis (Bell's stage III or IV) (17)
- Intraventricular haemorrhage (grade III or IV)

Serious adverse events

Serious adverse events (SAEs) are recorded within 7 days after the randomised extubation. All are prespecified secondary outcomes of ÉCLAT. The investigators are responsible for recording all events regardless of their relationship to the intervention. All SAE's are reported to an independent Data Safety Monitoring Committee (DSMC) and the local ethics committee within 72 hours of the principle investigator being notified. The following outcomes are designated as SAEs:

- Death
- Spontaneous intestinal perforation
- Pneumothorax
- Pulmonary interstitial emphysema

Study Oversight

The independent DMSC established for the ÉCLAT trial have their roles and responsibilities detailed in a separate DSMC Charter. The DSMC includes two independent, experienced neonatologists, and a senior statistician. The terms of reference for the DSMC include performance of interim safety analyses, periodic examination of relevant emerging external evidence, monitoring of adverse events, compliance with the trial protocol, and progress of recruitment. Safety analyses by the DMSC are planned after the primary outcome is known for the first 50 and 100 infants and will occur blinded to group allocation. If required, an additional safety analysis will be performed at 150 infants. No interim analyses of the primary outcome are planned.

Clinical Significance

Extubation failure is common in extremely preterm infants and associated with important neonatal morbidities (18). CPAP is the most commonly used form of non-invasive ventilation used post-extubation but the optimal pressure to use for this indication remains uncertain. The ÉCLAT study will reveal novel information regarding CPAP pressures in extremely preterm infants. The ÉCLAT study is the largest trial comparing and researching CPAP pressures >8 cm H₂O. Results from ÉCLAT will inform clinical practice and support clinicians in understanding and optimising CPAP pressures for extremely preterm infants. Results from this study will be disseminated via peer-reviewed journals and presented at national and international scientific conferences.

Author Statement

RB, AM and AK developed the concept and RB and AK wrote the protocol. BM, RAB, AM and PD gave input into the protocol and revised the manuscript. SD designed the statistical analysis and revised the manuscript. All authors have read and approved the final manuscript and are accountable for its accuracy.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. However, AK would like to thank the centre for research excellence in Newborn Medicine for their support NHMRC, GNT 1153176.

Competing interests

None declared.

References

1. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, te Pas A, et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome – 2019 Update. *Neonatology*. 2019;115(4):432–50.
2. Shalish W, Kanbar L, Kovacs L, Chawla S, Keszler M, Rao S, et al. The Impact of Time Interval between Extubation and Reintubation on Death or Bronchopulmonary Dysplasia in Extremely Preterm Infants. *J Pediatr*. 2019 Feb;205:70-76.e2.
3. Chawla S, Natarajan G, Shankaran S, Carper B, Brion LP, Keszler M, et al. Markers of Successful Extubation in Extremely Preterm Infants, and Morbidity After Failed Extubation. *J Pediatr*. 2017 Oct;189:113-119.e2.
4. Teixeira RF, Carvalho ACA, de Araujo RD, Veloso FCS, Kassab SB, Medeiros AMC. Spontaneous Breathing Trials in Preterm Infants: Systematic Review and Meta-Analysis. *Respir Care*. 2021 Jan;66(1):129–37.
5. Manley BJ, Doyle LW, Owen LS, Davis PG. Extubating Extremely Preterm Infants: Predictors of Success and Outcomes following Failure. *J Pediatr*. 2016 Jun;173:45–9.
6. Davis PG, Henderson-Smart DJ. Nasal continuous positive airways pressure immediately after extubation for preventing morbidity in preterm infants. *Cochrane Database Syst Rev*. 2003;(2):CD000143.
7. Kitsommart R, MHSc AK, Al-Saleem N, Rnc MJ, Sant’Anna GM. Levels of Nasal CPAP Applied During the Immediate Post- Extubation Phase: A Randomized Controlled Pilot Trial. 2013;3(1):9.
8. Buzzella B, Claire N, D’Ugard C, Bancalari E. A Randomized Controlled Trial of Two Nasal Continuous Positive Airway Pressure Levels after Extubation in Preterm Infants. *J Pediatr*. 2014 Jan;164(1):46–51.
9. Roehr CC. CPAP in Neonates: Current Methods and Further Improvements. In: Esquinas AM, Fiorentino G, Insalaco G, Mina B, Duan J, Mondardini MC, et al., editors. *Noninvasive Ventilation in Sleep Medicine and Pulmonary Critical Care: Critical Analysis of 2018-19 Clinical Trials* [Internet]. Cham: Springer International Publishing; 2020. p. 465–75. Available from: https://doi.org/10.1007/978-3-030-42998-0_51
10. Jois RS. Understanding long-term neurodevelopmental outcomes of very and extremely preterm infants: A clinical review. *Aust J Gen Pract*. 2019 Jan 1;48(1–2):26–31.
11. Thébaud B, Goss KN, Laughon M, Whitsett JA, Abman SH, Steinhorn RH, et al. Bronchopulmonary dysplasia. *Nat Rev Dis Primer*. 2019 Dec;5(1):78.
12. Thomas RE, Rao SC, Minutillo C, Vijayasekaran S, Nathan EA. Severe acquired subglottic stenosis in neonatal intensive care graduates: a case–control study. *Arch Dis Child - Fetal Neonatal Ed*. 2018 Jul;103(4):F349–54.

13. Jadcherla SR, Wang M, Vijayapal AS, Leuthner SR. Impact of prematurity and co-morbidities on feeding milestones in neonates: a retrospective study. *J Perinatol*. 2010 Mar;30(3):201–8.
14. Janvier A. *Breathe, Baby, Breathe!: Neonatal Intensive Care, Prematurity, and Complicated Pregnancies*. University of Toronto Press; 2020.
15. Chan A-W, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. *BMJ*. 2013 Jan 9;346(jan08 15):e7586–e7586.
16. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009 Apr;42(2):377–81.
17. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal Necrotizing Enterocolitis: Therapeutic Decisions Based upon Clinical Staging. *Ann Surg*. 1978 Jan;187(1):1–7.
18. Gupta D, Greenberg RG, Sharma A, Natarajan G, Cotten M, Thomas R, et al. A predictive model for extubation readiness in extremely preterm infants. *J Perinatol*. 2019 Dec;39(12):1663–9.

List of figures:

Figure 1: Study Procedure

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46


Supplemental file 1:

Model Participant Information and Consent Form

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Study Procedure



ÉCLAT Study Procedure

146x90mm (300 x 300 DPI)

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586

		Page
	Reporting Item	Number
Administrative information		
Title	#1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	2

1	Trial registration	#2a	Trial identifier and registry name. If not yet registered,	1
2			name of intended registry	
3				
4				
5				
6	Trial registration:	#2b	All items from the World Health Organization Trial	1
7				
8	data set		Registration Data Set	
9				
10				
11				
12	Protocol version	#3	Date and version identifier	1
13				
14				
15	Funding	#4	Sources and types of financial, material, and other	11
16			support	
17				
18				
19				
20	Roles and	#5a	Names, affiliations, and roles of protocol contributors	1
21				
22	responsibilities:			
23				
24	contributorship			
25				
26				
27				
28	Roles and	#5b	Name and contact information for the trial sponsor	11
29				
30	responsibilities:			
31				
32	sponsor contact			
33				
34	information			
35				
36				
37				
38	Roles and	#5c	Role of study sponsor and funders, if any, in study	N/A
39			design; collection, management, analysis, and	
40	responsibilities:		interpretation of data; writing of the report; and the	
41			decision to submit the report for publication, including	
42	sponsor and funder		whether they will have ultimate authority over any of	
43			these activities	
44				
45				
46				
47				
48				
49				
50				
51				
52	Roles and	#5d	Composition, roles, and responsibilities of the	1,10,11
53			coordinating centre, steering committee, endpoint	
54	responsibilities:		adjudication committee, data management team, and	
55				
56	committees			
57				
58				
59				
60				

other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)

Introduction

Background and rationale	#6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	3,4
Background and rationale: choice of comparators	#6b	Explanation for choice of comparators	4
Objectives	#7	Specific objectives or hypotheses	4
Trial design	#8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	4
Methods:			
Participants, interventions, and outcomes			
Study setting	#9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	4

1	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If	5
2			applicable, eligibility criteria for study centres and	
3			individuals who will perform the interventions (eg,	
4			surgeons, psychotherapists)	
5				
6				
7				
8				
9				
10				
11	Interventions:	#11a	Interventions for each group with sufficient detail to	4,5
12			allow replication, including how and when they will be	
13	description		administered	
14				
15				
16				
17				
18				
19	Interventions:	#11b	Criteria for discontinuing or modifying allocated	6
20			interventions for a given trial participant (eg, drug dose	
21	modifications		change in response to harms, participant request, or	
22			improving / worsening disease)	
23				
24				
25				
26				
27				
28				
29	Interventions:	#11c	Strategies to improve adherence to intervention	6
30			protocols, and any procedures for monitoring adherence	
31	adherence		(eg, drug tablet return; laboratory tests)	
32				
33				
34				
35				
36	Interventions:	#11d	Relevant concomitant care and interventions that are	7
37			permitted or prohibited during the trial	
38	concomitant care			
39				
40				
41				
42	Outcomes	#12	Primary, secondary, and other outcomes, including the	7,8,9
43			specific measurement variable (eg, systolic blood	
44			pressure), analysis metric (eg, change from baseline,	
45			final value, time to event), method of aggregation (eg,	
46			median, proportion), and time point for each outcome.	
47				
48				
49				
50				
51				
52				
53			Explanation of the clinical relevance of chosen efficacy	
54			and harm outcomes is strongly recommended	
55				
56				
57				
58				
59				
60				

1	Participant timeline	#13	Time schedule of enrolment, interventions (including	6
2			any run-ins and washouts), assessments, and visits for	
3			participants. A schematic diagram is highly	
4			recommended (see Figure)	
5				
6				
7				
8				
9				
10				
11	Sample size	#14	Estimated number of participants needed to achieve	4
12			study objectives and how it was determined, including	
13			clinical and statistical assumptions supporting any	
14			sample size calculations	
15				
16				
17				
18				
19				
20				
21	Recruitment	#15	Strategies for achieving adequate participant enrolment	4
22			to reach target sample size	
23				
24				
25				
26	Methods:			
27				
28	Assignment of			
29	interventions (for			
30	controlled trials)			
31				
32				
33				
34				
35				
36	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	5
37	generation		computer-generated random numbers), and list of any	
38			factors for stratification. To reduce predictability of a	
39			random sequence, details of any planned restriction (eg,	
40			blocking) should be provided in a separate document	
41			that is unavailable to those who enrol participants or	
42			assign interventions	
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53	Allocation	#16b	Mechanism of implementing the allocation sequence	5
54	concealment		(eg, central telephone; sequentially numbered, opaque,	
55				
56				
57				
58	mechanism			

1		sealed envelopes), describing any steps to conceal the	
2		sequence until interventions are assigned	
3			
4			
5			
6	Allocation:	#16c Who will generate the allocation sequence, who will	5
7			
8	implementation	enrol participants, and who will assign participants to	
9		interventions	
10			
11			
12			
13	Blinding (masking)	#17a Who will be blinded after assignment to interventions	N/A
14			
15		(eg, trial participants, care providers, outcome	
16		assessors, data analysts), and how	
17			
18			
19			
20			
21	Blinding (masking):	#17b If blinded, circumstances under which unblinding is	N/A
22			
23	emergency	permissible, and procedure for revealing a participant's	
24		allocated intervention during the trial	
25	unblinding		
26			
27			
28			
29	Methods: Data		
30			
31	collection,		
32			
33	management, and		
34			
35	analysis		
36			
37			
38			
39	Data collection plan	#18a Plans for assessment and collection of outcome,	9
40		baseline, and other trial data, including any related	
41		processes to promote data quality (eg, duplicate	
42		measurements, training of assessors) and a description	
43		of study instruments (eg, questionnaires, laboratory	
44		tests) along with their reliability and validity, if known.	
45			
46		Reference to where data collection forms can be found,	
47			
48		if not in the protocol	
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			

1	Data collection plan:	#18b	Plans to promote participant retention and complete	N/A no
2				
3	retention		follow-up, including list of any outcome data to be	long term
4			collected for participants who discontinue or deviate	follow-up
5			from intervention protocols	
6				
7				
8				
9				
10				
11	Data management	#19	Plans for data entry, coding, security, and storage,	5
12			including any related processes to promote data quality	
13			(eg, double data entry; range checks for data values).	
14			Reference to where details of data management	
15			procedures can be found, if not in the protocol	
16				
17				
18				
19				
20				
21				
22				
23	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	4
24			outcomes. Reference to where other details of the	
25			statistical analysis plan can be found, if not in the	
26			protocol	
27				
28				
29				
30				
31				
32				
33	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	4
34	analyses		adjusted analyses)	
35				
36				
37				
38				
39	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	4
40	population and		adherence (eg, as randomised analysis), and any	
41	missing data		statistical methods to handle missing data (eg, multiple	
42			imputation)	
43				
44				
45				
46				
47				
48	Methods: Monitoring			
49				
50				
51	Data monitoring:	#21a	Composition of data monitoring committee (DMC);	10
52	formal committee		summary of its role and reporting structure; statement of	
53			whether it is independent from the sponsor and	
54				
55				
56				
57				
58				
59				
60				

competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed

1			
2			
3			
4			
5			
6			
7			
8			
9			
10	Data monitoring:	#21b	Description of any interim analyses and stopping
11			
12	interim analysis		guidelines, including who will have access to these
13			
14			interim results and make the final decision to terminate
15			the trial
16			
17			
18			
19			
20	Harms	#22	Plans for collecting, assessing, reporting, and managing
21			solicited and spontaneously reported adverse events
22			
23			and other unintended effects of trial interventions or trial
24			conduct
25			
26			
27			
28			
29			
30	Auditing	#23	Frequency and procedures for auditing trial conduct, if
31			any, and whether the process will be independent from
32			investigators and the sponsor
33			
34			
35			
36			
37			
38	Ethics and		
39			
40	dissemination		
41			
42			
43	Research ethics	#24	Plans for seeking research ethics committee /
44			
45	approval		institutional review board (REC / IRB) approval
46			
47			
48	Protocol	#25	Plans for communicating important protocol
49			
50	amendments		modifications (eg, changes to eligibility criteria,
51			outcomes, analyses) to relevant parties (eg,
52			investigators, REC / IRBs, trial participants, trial
53			registries, journals, regulators)
54			
55			
56			
57			
58			
59			
60			

1	Consent or assent	#26a	Who will obtain informed consent or assent from	7,8
2			potential trial participants or authorised surrogates, and	
3			how (see Item 32)	
4				
5				
6				
7				
8				
9	Consent or assent:	#26b	Additional consent provisions for collection and use of	N/A
10	ancillary studies		participant data and biological specimens in ancillary	
11			studies, if applicable	
12				
13				
14				
15				
16	Confidentiality	#27	How personal information about potential and enrolled	10
17			participants will be collected, shared, and maintained in	
18			order to protect confidentiality before, during, and after	
19			the trial	
20				
21				
22				
23				
24				
25				
26	Declaration of	#28	Financial and other competing interests for principal	11
27	interests		investigators for the overall trial and each study site	
28				
29				
30				
31				
32	Data access	#29	Statement of who will have access to the final trial	9
33			dataset, and disclosure of contractual agreements that	
34			limit such access for investigators	
35				
36				
37				
38				
39	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care, and	N/A
40	trial care		for compensation to those who suffer harm from trial	
41			participation	
42				
43				
44				
45				
46				
47	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate trial	2
48	trial results		results to participants, healthcare professionals, the	
49			public, and other relevant groups (eg, via publication,	
50			reporting in results databases, or other data sharing	
51			arrangements), including any publication restrictions	
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Dissemination policy: #31b	Authorship eligibility guidelines and any intended use of	2
2			
3	authorship	professional writers	
4			
5			
6	Dissemination policy: #31c	Plans, if any, for granting public access to the full	N/A
7			
8	reproducible	protocol, participant-level dataset, and statistical code	
9			
10	research		
11			
12			
13			
14	Appendices		
15			
16			
17	Informed consent	#32 Model consent form and other related documentation	15
18			
19	materials	given to participants and authorised surrogates	
20			
21			
22	Biological specimens	#33 Plans for collection, laboratory evaluation, and storage	N/A
23			
24		of biological specimens for genetic or molecular analysis	
25			
26		in the current trial and for future use in ancillary studies,	
27			
28		if applicable	
29			
30			
31			

Notes:

- 18b: N/A no long term follow-up The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND 3.0. This checklist was completed on 03. February 2021 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

Protocol for a Randomised Controlled Trial Comparing Two CPAP Levels to Prevent Extubation failure in Extremely Preterm Infants

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-045897.R2
Article Type:	Protocol
Date Submitted by the Author:	12-May-2021
Complete List of Authors:	Kidman, Anna; The University of Melbourne Faculty of Medicine Dentistry and Health Sciences, Obstetrics and Gynaecology ; Monash Newborn at Monash Children's Hospital, Monash Newborn Manley, Brett; The University of Melbourne Department of Obstetrics and Gynaecology; The Royal Women's Hospital, Newborn Research Centre Boland, Rosemarie Anne; The University of Melbourne Faculty of Medicine Dentistry and Health Sciences, Obstetrics and Gynaecology ; Murdoch Childrens Research Institute Malhotra, Atul; Monash Newborn at Monash Children's Hospital, Monash Newborn; Monash University, Paediatrics Donath, Susan; Murdoch Childrens Research Institute, Clinical Epidemiology and Biostatistics Unit Davis, Peter; The University of Melbourne Faculty of Medicine Dentistry and Health Sciences, Obstetrics and Gynaecology ; The Royal Women's Hospital, Newborn Research Bhatia, Risha; Monash Newborn at Monash Children's Hospital; Monash University, Paediatrics
Primary Subject Heading:	Paediatrics
Secondary Subject Heading:	Intensive care, Obstetrics and gynaecology
Keywords:	Neonatal intensive & critical care < INTENSIVE & CRITICAL CARE, NEONATOLOGY, RESPIRATORY MEDICINE (see Thoracic Medicine)

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Title Page

Title:

Protocol for a Randomised Controlled Trial Comparing Two CPAP Levels to Prevent Extubation failure in Extremely Preterm Infants.

Authors

* [Kidman, A.M.](#)¹⁻³, Manley, B.J.^{1,3,4}, Boland, R.A.^{1,4}, Malhotra, A.^{2,5,6}, Donath, S.⁴, Davis, P.G.^{1,3,4}, and Bhatia, R.^{2,5}.

Affiliations:

1. The University of Melbourne Faculty of Medicine Dentistry and Health Sciences, Obstetrics and Gynaecology Melbourne, VIC, AUS
2. Monash Newborn at Monash Children's Hospital, Monash Newborn
3. The Royal Women's Hospital, Newborn Research Centre Level 7, 20 Flemington Road Parkville, VIC, AUS
4. Murdoch Children's Research Institute, Clinical Epidemiology and Biostatistics Unit Melbourne, VIC, AUS
5. Monash University, Paediatrics Clayton, VIC, AUS
6. The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Australia

Contact Details:

* akidman@student.unimelb.edu.au

Anna Kidman

The University of Melbourne
Faculty of Medicine Dentistry and Health Sciences
Obstetrics and Gynaecology
Newborn Research
20 Flemington Road
Parkville, VIC
Australia 3052

Trial Registration

Australia and New Zealand Clinical Trial Registry: ACTRN12618001638224

Keywords:

Extremely preterm, infant, endotracheal extubation, continuous positive airway pressure.

Data sharing statement:

The protocol will be published and publicly available, and the de-identified individual patient datasets and statistical codes will be available on reasonable request.

Word count: 2604

Abstract

Introduction: Respiratory distress syndrome (RDS) is a complication of prematurity and extremely preterm infants born before 28 weeks' gestation often require endotracheal intubation and mechanical ventilation. In this high-risk population, mechanical ventilation is associated with lung injury and contributes to bronchopulmonary dysplasia. Therefore, clinicians attempt to extubate infants as quickly and use non-invasive respiratory support such as nasal continuous positive airway pressure (CPAP) to facilitate the transition. However, approximately 60% of extremely preterm infants experience 'extubation failure' and require re-intubation. Whilst CPAP pressures of 5-8cmH₂O are commonly used, the optimal CPAP pressure is unknown, and higher pressures may be beneficial in avoiding extubation failure. Our trial is the Extubation CPAP Level Assessment Trial (ÉCLAT). The aim of this trial is to compare higher CPAP pressures 9-11cmH₂O with a current standard pressures of 6-8cmH₂O on extubation failure in extremely preterm infants.

Methods and analysis: 200 extremely preterm infants will be recruited prior to their first extubation from mechanical ventilation to CPAP. This is a parallel group randomised controlled trial. Infants will be randomised to one of two set CPAP pressures: CPAP10cmH₂O (intervention) or CPAP 7cmH₂O (control). The primary outcome will be extubation failure (re-intubation) within seven-days. Statistical analysis will follow standard methods for randomised trials on an intention to treat basis. For the primary outcome, this will be by intention to treat, adjusted for the pre-randomisation strata (GA and centre). We will use the appropriate parametric and non-parametric statistical tests.

Ethics and dissemination: Ethics approval has been granted by the Monash Health Human Research Ethics Committees. Amendments to the trial protocol will be submitted for approval. The findings of this study will be written into a clinical trial report manuscript and disseminated

1
2
3 via peer-reviewed journals (on-line or in press) and presented at national and international
4 conferences. This trial was prospectively registered with Australia and New Zealand Clinical
5 Trial Registry ACTRN12618001638224.
6
7
8
9

10 **Article Summary**

11 **Strengths and limitations of this study:**

- 12 • This study is a multicentre randomised controlled trial
- 13 • This study is the largest trial comparing CPAP pressure ranges to reduce extubation
14 failure in extremely preterm infants
- 15 • CPAP pressures as high as 9-11cm H₂O are yet to be formally evaluated in extremely
16 preterm infants
- 17 • Due to the nature of the interventions blinding of patients and clinicians are unable to
18 occur.
19
20
21
22
23
24
25
26

27 **Introduction**

28
29 Respiratory distress syndrome (RDS) is common in preterm infants, and almost universal in
30 extremely preterm infants born <28 weeks' gestation. In this high-risk population,
31 bronchopulmonary dysplasia (BPD), the chronic lung disease of prematurity, is a major
32 morbidity following RDS and its treatment (1). Many extremely preterm infants require
33 endotracheal intubation and mechanical ventilation (1). Mechanical ventilation, particularly if
34 prolonged, injures the lungs and contributes to BPD (2). Consequently, avoiding or minimising
35 the time that extremely preterm infants are mechanically ventilated is critical.
36
37
38
39
40

41 The optimal way to provide respiratory support to extremely preterm infants after
42 mechanical ventilation remains under investigation, and the transition from mechanical
43 ventilation to non-invasive respiratory support remains a poorly understood process (2). There
44 is a paucity of data on the optimal timing of extubation, criteria for readiness for extubation,
45 and the best strategy to use when providing post-extubation respiratory support (3). The
46 extubation failure rate in extremely preterm infants is high (4), and reducing this outcome must
47 be a focus of research.
48
49
50
51
52

53 Nasal continuous positive airway pressure (CPAP) is the most frequently used mode of
54 non-invasive support used after extubation of extremely preterm infants. The reasons for
55 extubation failure during CPAP are multifactorial. Variables such as infant weight (birth weight
56 <750g), immaturity (<26 weeks' gestation) and the severity of RDS (alveolar-arterial gradient
57 >180 mm Hg) are weakly predictive of early CPAP failure in very preterm infants (5). The use
58
59
60

1
2
3 of a set CPAP pressure sufficient to maintain functional residual capacity is likely to be
4 important (6). The optimal CPAP pressure to use after extubation is unknown, although a meta-
5 analysis of studies suggests that pressures of at least 5 cm H₂O are needed (6). Many infants
6 are re-intubated following extubation for increased oxygen requirement and work of breathing
7 suggesting that a low end-expiratory lung volume may contribute to extubation failure (5).
8
9

10
11 Utilising higher CPAP pressures post-extubation may prevent alveolar collapse,
12 improve lung function and reduce extubation failure (7,8). Kitsommart *et al* compared CPAP
13 7-9 cm H₂O with CPAP 4-6 cm H₂O after extubation of infants with birth weight <1250 g and
14 demonstrated no difference in extubation failure within 72 hours (7). In a second trial, Buzzella
15 *et al* randomised very preterm infants born 23-30 weeks' gestation with RDS to receive either
16 CPAP 7-9 cm H₂O or CPAP 4-6 cm H₂O after extubation (8). Rates of extubation failure within
17 96 hours were significantly lower in the group randomised to the higher range of CPAP
18 pressures (8). Current CPAP pressure recommendations are wide and varied (6). Most
19 clinicians report pressures of 5-8 cm H₂O however, use of CPAP pressures up to 12 cm H₂O
20 have been reported and have not been associated with adverse effects (9).
21
22
23
24
25
26
27
28

29 In extremely preterm infants, extubation failure is associated with significant
30 morbidities, including BPD, pulmonary vascular disease, airway trauma, poor feeding and oral
31 aversion, adverse neurodevelopmental outcomes, and delayed family unit bonding (10). Thus,
32 improving rates of successful extubation in this high-risk population of preterm infants is a
33 clinical priority (10–14). The ÉCLAT trial will investigate the CPAP pressure range of 6-8 cm
34 H₂O, routinely used in our clinical practice, with a higher-pressure range of 9-11 cm H₂O. We
35 hypothesise that the higher-pressure range will result in less atelectatic pulmonary failure and
36 extubation failure.
37
38
39
40
41
42
43
44

45 **Methods and analysis**

46 **Study design and aim**

47 We used the SPIRIT checklist when writing our report (15). This is a multicentre, unblinded,
48 randomised controlled trial. The aim of the ÉCLAT study is to determine, in extremely preterm
49 infants born <28 weeks' gestation who are undergoing their first extubation, whether
50 extubation to a higher CPAP pressure (10 cm H₂O, range 9-11 cm H₂O), compared with a
51 standard CPAP pressure (7 cm H₂O, range 6-8 cm H₂O) decreases extubation failure within
52 seven days.
53
54
55
56
57
58

59 **Sample size**

1
2
3 The rates of extubation failure within 7 days in extremely preterm infants at the participating
4 centres is estimated at 55%. To detect a reduction in extubation failure from 55% to 35%
5 (absolute risk reduction 20%, relative risk reduction 40%) with 80% power and a two-tailed
6 alpha error of 0.05, a sample size of 93 infants in each arm (total 186 infants) is required.
7
8
9

10 **Patient population**

11 Infants born extremely preterm (<28 weeks' gestation) who are intubated and
12 mechanically ventilated and being extubated for the first time are eligible for participation in
13 the ÉCLAT trial. The timing of the extubation is determined by the clinical team caring for the
14 infant, and there is no postnatal age limit for participation.
15
16
17
18
19

20 **Inclusion criteria**

21 Infants are eligible if they:

- 22 • were born <28 completed weeks' gestation
- 23 • are being extubated for the first time from mechanical ventilation to nasal CPAP
- 24 • have received enteral or intravenous caffeine (as prophylaxis for apnoea of prematurity)
25 <24 hours prior to the planned extubation
- 26 • have received exogenous surfactant treatment.
- 27
28
29
30
31
32
33

34 **Exclusion criteria**

35 Infants are excluded if they:

- 36 • are being extubated to any other mode of non-invasive respiratory support other than nasal
37 CPAP, or to no respiratory support
- 38 • have a major congenital anomaly or condition that might adversely affect breathing or
39 ventilation: e.g. known upper airway obstruction or major airway abnormality, or major
40 congenital heart disease
- 41 • are not receiving full intensive care after extubation.
- 42
43
44
45
46
47
48
49

50 **Randomisation**

51 Enrolled infants are randomised using REDCap electronic data capture tools (16),
52 hosted at the Murdoch Children's Research Institute, Melbourne, Australia. REDCap
53 (Research Electronic Data Capture) is a secure, password encrypted, web-based application
54 designed to support data capture and randomisation for research studies. Only the infant's first
55 extubation is randomised. Multiple births are randomised individually. Randomisation occurs
56
57
58
59
60

1
2
3 after the clinical decision to extubate has been made and shortly before extubation using a
4 computer or smartphone. Stratification is by centre and gestational age at birth (<26 weeks;
5 ≥26 weeks).
6
7
8
9

10 **Clinical Management [Figure one]**

11 **Higher CPAP pressure (Intervention)**

12
13
14
15 Infants are extubated to a set CPAP pressure of **10 cm H₂O**. Whilst receiving CPAP, infants
16 will remain within a set CPAP pressure range of **9 cm H₂O – 11 cm H₂O** for at least **24 hours**,
17 with changes within this range at the discretion of the treating team. After 24 hours, infants
18 may have their set CPAP pressure weaned at the discretion of the treating team but must remain
19 within a set CPAP pressure range **5 cm H₂O – 11 cm H₂O** for at least **7 days** after extubation
20 if receiving CPAP. Infants are re-intubated if they satisfy the extubation failure criteria
21 described below within 7 days after extubation. The fraction of inspired oxygen (FiO₂) is
22 titrated to keep oxygen saturations (SpO₂) in the standard target ranges of the participating
23 unit. If extubation failure occurs, management following re-intubation will be at the discretion
24 of the treating team. For subsequent extubations, clinicians will be encouraged to use the
25 assigned set CPAP pressure range (see figure one).
26
27
28
29
30
31
32
33
34
35

36 **Standard CPAP pressure (control)**

37
38 Infants are extubated to a set CPAP pressure of **7 cm H₂O**. Whilst receiving CPAP, infants will
39 remain within a set CPAP pressure range of **6 cm H₂O – 8 cm H₂O** for at least **24 hours**, with
40 changes to the set CPAP pressure within this range at the discretion of the treating team. After
41 24 hours, infants may have their set CPAP pressure weaned at the discretion of the treating
42 team but must remain within a set CPAP pressure range **5 cm H₂O – 8 cm H₂O** for at least **7**
43 **days** after extubation if receiving CPAP. Infants are re-intubated if they satisfy the extubation
44 failure criteria described below within 7 days after extubation. The FiO₂ is titrated to keep SpO₂
45 in the standard target ranges of the participating unit. If extubation failure occurs, management
46 following re-intubation will be at the discretion of the treating team. For subsequent
47 extubations, clinicians will be encouraged to use the assigned set CPAP pressure range (see
48 figure one).
49
50
51
52
53
54
55
56
57

58 **Device**

1
2
3 In both groups, infants will be extubated to continuous-flow nasal CPAP, via a mechanical
4 ventilator (either the Dräger VN500, Dräger Medical, Lübeck, Germany, or the SLE 5000,
5 SLE, Croydon, UK) operating in CPAP mode. After 24 hours the infant may be transitioned to
6 ‘bubble’ nasal CPAP (Fisher & Paykel bubble CPAP circuit, Fisher & Paykel Healthcare,
7 Auckland, New Zealand) but only if receiving a CPAP $\leq 10\text{cmH}_2\text{O}$ given the pressure
8 limitations of the ‘bubble’ CPAP device. Nasal CPAP may be delivered via any binasal CPAP
9 prongs or mask, according to the participating unit’s protocol. Nasal prongs should be sized as
10 per the manufactures guidelines to the largest size to occlude the infant’s nares.
11
12
13
14
15
16
17
18

19 **Outcomes**

20 **Extubation Failure**

21 The primary outcome is extubation failure within 7 days, defined as receiving the *maximum*
22 CPAP level (11 cm H₂O in the intervention group; 8 cm H₂O in the control group) and having
23 at least one of:
24
25
26

- 27 • FiO₂ requirement >0.20 above the pre-extubation FiO₂
- 28 • Two or more apnoeic episodes within any 24-hour period requiring intermittent positive
29 pressure ventilation, or six or more apnoeic events requiring stimulation in any 6-hour
30 period
- 31 • Respiratory acidosis with pH <7.2 and pCO₂ >60 mm Hg
- 32 • Require urgent intubation for an acute deterioration (at clinical discretion) with the reason
33 for re-intubation documented.
- 34
35
36
37
38
39
40
41

42 **Treatment failure**

43 Should infants not be immediately reintubated and instead managed with non-invasive positive
44 pressure ventilation or escalated to a higher CPAP pressure than their assigned range they will
45 be documented as an extubation failure and reported as a protocol violation.
46
47
48
49

50 **Secondary outcomes**

- 51 • Incidence of re-intubation within 72 hours, and within 96 hours
- 52 • Failure in hours after extubation
 - 53 ○ Reason(s) for extubation failure
 - 54 ○ Kaplan Meier Survival curve between both groups
- 55 • Death before hospital discharge
- 56
57
58
59
60

- Duration of mechanical ventilation in days after randomisation in survivors
- Total duration of hospitalisation in days in survivors
- Postmenstrual age at last supplemental oxygen, and at last positive pressure ventilation (mechanical ventilation, CPAP [or variants], or nasal high-flow >2 Litres per minute) in survivors
- Incidence of treatment with systemic postnatal corticosteroids for lung disease after randomisation
- Incidence of new pneumothorax requiring drainage with thoracocentesis or intercostal catheter insertion after randomisation
- Incidence of new, radiologically-diagnosed pulmonary interstitial emphysema after randomisation
- Incidence of BPD, defined as a requirement for supplemental oxygen and/or respiratory support (mechanical ventilation, CPAP [or variants], or nasal high-flow >2 Litres per minute) at 36 weeks' post-menstrual age
- Incidence of necrotising enterocolitis Bell's stage 2 or above after randomisation (17)
- Incidence of spontaneous intestinal perforation after randomisation
- Incidence of retinopathy of prematurity requiring treatment with laser therapy or intra-ocular medication in one or both eyes after randomisation
- Incidence of new diagnosis of grade 3 or 4 intraventricular haemorrhage after randomisation

Other data

Data collected will include:

- Maternal and infant demographics: maternal parity, infant sex, gestational age at birth, birth weight in grams, mode of delivery, exposure to any antenatal corticosteroids, duration of ruptured membranes prior to delivery in days, presence of histologically diagnosed chorioamnionitis
- Postnatal age at extubation in days, last weight prior to extubation in grams, age at first intubation in hours
- Previous dose of exogenous surfactant received in milligrams/kilogram, prior treatment for a patent ductus arteriosus (pharmacological or surgical), prior systemic postnatal corticosteroids for lung disease

- Mechanical ventilator settings immediately prior to extubation (mode, mean airway pressure in mmHg, FiO₂, tidal volumes (set and achieved), peak pressures (set and achieved) and end expiratory pressure.
- Blood gas analysis results within 24 hours prior to extubation (if applicable): lowest pH, highest pCO₂, lowest base excess.

Data analysis plan

Statistical analysis will follow standard methods for randomised trials. For the primary outcome, the analysis will be by intention to treat and be adjusted for the pre-randomisation strata (GA and centre). For dichotomous outcomes, including the primary outcome, the two treatment groups will be compared using risk difference with 95% CI, both overall, and within the pre-specified subgroups (gestational age at birth <26 weeks, ≥26 weeks). For dichotomous secondary outcomes, analysis will be limited to the two treatment groups, using risk difference with 95% CI. For continuous outcomes, the two treatment groups will be compared using difference of means, together with 95% CI, for outcome variables which are normally distributed; for outcome variables, which are not normally distributed, the comparison will be difference of medians, with 95% CI. All comparisons (risk difference, difference of means, difference of medians) will be estimated using regression models with the randomisation strata as covariates, and with standard errors adjusted to take into account the clustering due to multiple births. Reporting of findings will be done in accordance with CONSORT guidelines.

Ethics and Dissemination

Infants are only enrolled after prospective, informed, written parental consent (see supplementary file). Parent(s) of eligible infants will be approached by a member of the research team. A verbal explanation of the study and a Parent Information and Consent Form will be provided. Where the parents of an eligible infant do not speak English sufficient to give informed consent, interpreters will be used to assist with the consent process.

The ÉCLAT study has received ethics approval from the Human Research Ethics Committees of The Royal Women's Hospital, Melbourne, Australia and Monash Health, Melbourne, Australia.

Patient and public involvement

Both human research and ethics committees at each recruitment centre have consumer input before trial approval to determine suitability of study design and consent forms. Consumer input was in the form of a consumer advocate, this is a panel of non-clinical public who have had previous involvement in a neonatal intensive care setting for example, a previous parent.

Adverse events

Adverse events (AEs) are recorded within 7 days after the randomised extubation. They are recorded as part of the study design and secondary outcomes of ÉCLAT. The site investigators are responsible for recording all AEs regardless of their relationship to the intervention. The following outcome are designated as AEs:

- Necrotising enterocolitis (Bell's stage III or IV) (17)
- Intraventricular haemorrhage (grade III or IV)

Serious adverse events

Serious adverse events (SAEs) are recorded within 7 days after the randomised extubation. All are prespecified secondary outcomes of ÉCLAT. The investigators are responsible for recording all events regardless of their relationship to the intervention. All SAE's are reported to an independent Data Safety Monitoring Committee (DSMC) and the local ethics committee within 72 hours of the principle investigator being notified. The following outcomes are designated as SAEs:

- Death
- Spontaneous intestinal perforation
- Pneumothorax
- Pulmonary interstitial emphysema

Study Oversight

The independent DSMC established for the ÉCLAT trial have their roles and responsibilities detailed in a separate DSMC Charter. The DSMC includes two independent, experienced neonatologists, and a senior statistician. The terms of reference for the DSMC include performance of interim safety analyses, periodic examination of relevant emerging external evidence, monitoring of adverse events, compliance with the trial protocol, and progress of recruitment. Safety analyses by the DSMC are planned after the primary outcome is known for the first 50 and 100 infants and will occur blinded to group allocation. If required,

1
2
3 an additional safety analysis will be performed at 150 infants. No interim analyses of the
4 primary outcome are planned.
5

6 **Clinical Significance**

7
8 Extubation failure is common in extremely preterm infants and associated with
9 important neonatal morbidities (18). CPAP is the most commonly used form of non-invasive
10 ventilation used post-extubation but the optimal pressure to use for this indication remains
11 uncertain. The ÉCLAT study will reveal novel information regarding CPAP pressures in
12 extremely preterm infants. The ÉCLAT study is the largest trial comparing and researching
13 CPAP pressures >8 cm H₂O. Results from ÉCLAT will inform clinical practice and support
14 clinicians in understanding and optimising CPAP pressures for extremely preterm infants.
15 Results from this study will be disseminated via peer-reviewed journals and presented at
16 national and international scientific conferences.
17
18
19
20
21
22
23
24

25 **Author Statement**

26
27 RB, AM and AK developed the concept and RB and AK wrote the protocol. BM, RAB,
28 AM and PD gave input into the protocol and revised the manuscript. SD designed the statistical
29 analysis and revised the manuscript. All authors have read and approved the final manuscript
30 and are accountable for its accuracy.
31
32
33
34
35

36 **Funding**

37 This research received no specific grant from any funding agency in the public, commercial
38 or not-for-profit sectors. However, AK would like to thank the centre for research excellence
39 in Newborn Medicine for their support NHMRC, GNT 1153176.
40
41
42
43

44 **Competing interests**

45 None declared.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, te Pas A, et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome – 2019 Update. *Neonatology*. 2019;115(4):432–50.
2. Shalish W, Kanbar L, Kovacs L, Chawla S, Keszler M, Rao S, et al. The Impact of Time Interval between Extubation and Reintubation on Death or Bronchopulmonary Dysplasia in Extremely Preterm Infants. *J Pediatr*. 2019 Feb;205:70-76.e2.
3. Chawla S, Natarajan G, Shankaran S, Carper B, Brion LP, Keszler M, et al. Markers of Successful Extubation in Extremely Preterm Infants, and Morbidity After Failed Extubation. *J Pediatr*. 2017 Oct;189:113-119.e2.
4. Teixeira RF, Carvalho ACA, de Araujo RD, Veloso FCS, Kassab SB, Medeiros AMC. Spontaneous Breathing Trials in Preterm Infants: Systematic Review and Meta-Analysis. *Respir Care*. 2021 Jan;66(1):129–37.
5. Manley BJ, Doyle LW, Owen LS, Davis PG. Extubating Extremely Preterm Infants: Predictors of Success and Outcomes following Failure. *J Pediatr*. 2016 Jun;173:45–9.
6. Davis PG, Henderson-Smart DJ. Nasal continuous positive airways pressure immediately after extubation for preventing morbidity in preterm infants. *Cochrane Database Syst Rev*. 2003;(2):CD000143.
7. Kitsommart R, MHSc AK, Al-Saleem N, Rnc MJ, Sant’Anna GM. Levels of Nasal CPAP Applied During the Immediate Post- Extubation Phase: A Randomized Controlled Pilot Trial. 2013;3(1):9.
8. Buzzella B, Claire N, D’Ugard C, Bancalari E. A Randomized Controlled Trial of Two Nasal Continuous Positive Airway Pressure Levels after Extubation in Preterm Infants. *J Pediatr*. 2014 Jan;164(1):46–51.
9. Roehr CC. CPAP in Neonates: Current Methods and Further Improvements. In: Esquinas AM, Fiorentino G, Insalaco G, Mina B, Duan J, Mondardini MC, et al., editors. *Noninvasive Ventilation in Sleep Medicine and Pulmonary Critical Care: Critical Analysis of 2018-19 Clinical Trials [Internet]*. Cham: Springer International Publishing; 2020. p. 465–75. Available from: https://doi.org/10.1007/978-3-030-42998-0_51
10. Jois RS. Understanding long-term neurodevelopmental outcomes of very and extremely preterm infants: A clinical review. *Aust J Gen Pract*. 2019 Jan 1;48(1–2):26–31.
11. Thébaud B, Goss KN, Laughon M, Whitsett JA, Abman SH, Steinhorn RH, et al. Bronchopulmonary dysplasia. *Nat Rev Dis Primer*. 2019 Dec;5(1):78.
12. Thomas RE, Rao SC, Minutillo C, Vijayasekaran S, Nathan EA. Severe acquired subglottic stenosis in neonatal intensive care graduates: a case–control study. *Arch Dis Child - Fetal Neonatal Ed*. 2018 Jul;103(4):F349–54.

13. Jadcherla SR, Wang M, Vijayapal AS, Leuthner SR. Impact of prematurity and co-morbidities on feeding milestones in neonates: a retrospective study. *J Perinatol*. 2010 Mar;30(3):201–8.
14. Janvier A. *Breathe, Baby, Breathe!: Neonatal Intensive Care, Prematurity, and Complicated Pregnancies*. University of Toronto Press; 2020.
15. Chan A-W, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. *BMJ*. 2013 Jan 9;346(jan08 15):e7586–e7586.
16. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009 Apr;42(2):377–81.
17. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal Necrotizing Enterocolitis: Therapeutic Decisions Based upon Clinical Staging. *Ann Surg*. 1978 Jan;187(1):1–7.
18. Gupta D, Greenberg RG, Sharma A, Natarajan G, Cotten M, Thomas R, et al. A predictive model for extubation readiness in extremely preterm infants. *J Perinatol*. 2019 Dec;39(12):1663–9.

List of figures:

Figure 1: Study Procedure

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46


Supplemental file 1:

Model Participant Information and Consent Form

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Study Procedure



ÉCLAT Study Procedure

146x90mm (300 x 300 DPI)

**Master Participant Information Sheet/Consent Form – Parent/Guardian
Interventional Study - Parent/Guardian consenting on behalf of participant**

Title	<i>Extubation CPAP Level Assessment Trial</i>
Short Title	<i>ÉCLAT</i>
Protocol Number	<i>1</i>
Project Sponsor	<i>Anna Kidman – PhD study</i>
Coordinating Principal Investigator/ Principal Investigator	<i>Anna Kidman & Dr Risha Bhatia (Monash Health)</i>
Associate Investigator(s)	<i>Dr Brett Manley (Royal Women’s Hospital) Dr Rose Boland (Royal Women’s Hospital) Professor Peter Davis (Royal Women’s Hospital)</i>
Location	<i>Monash Newborn & Royal Women’s Hospital</i>

Part 1 What does your baby’s participation involve?

1. Introduction

This is an invitation for your baby in your care to take part in this research project because they are currently intubated with an endotracheal tube. The research project is testing the use of different air pressures on an existing type of respiratory support *Continuous Positive Airway Pressure (CPAP)* after the endotracheal tube is removed.

This Participant Information Sheet/Consent Form informs you of the research project. It explains the tests and treatments involved. Knowing what is involved will help you decide if you want your baby to take part in the research.

Please read this information carefully. Ask questions about anything that you don’t understand or want to know more about. Before deciding whether or not your baby can take part, you might want to talk about it with a relative or friend.

Participation in this research is voluntary. If you do not wish your baby to take part, they do not have to. your baby will still receive the best possible care whether or not they take part. They will still receive the same CPAP care as those babies in the trial. The only difference will be your baby’s data will not be recorded and used to further develop the extubation process.

If you decide you want your baby to take part in the research project, you will be asked to sign the consent section. By signing it you are telling us that you:

- Understand what you have read
- Consent to your baby taking part in the research project
- Consent for your baby to have the tests and treatments that are described
- Consent to the use of your baby’s personal and health information as described.

You will be given a copy of this Participant Information and Consent Form to keep.

2. What is the purpose of this research?

Your premature baby is currently intubated with an endotracheal tube to help them breath because they are requiring extra support. Soon the treating team will want to remove this tube to let your baby breathe on his/her own (extubate). Most often extremely premature infants will still require a form of *non-invasive* breathing support after the tube is removed to help hold their lungs open for a period of time.

Neonatal intensive care units are currently using Continuous Positive Airway Pressure (CPAP) as this support. CPAP involves short soft prongs that sit in your baby's nose connected to a circuit that delivers a continuous amount of distending pressure (and or oxygen) into your baby's lungs. This amount of pressure is measured in cm H₂O and can range from 4-12.

At the moment most babies, once extubated are prescribed a level of 7 cm H₂O. Sometimes a baby is not ready to have the breathing tube removed and so needs to be re-intubated.

The aim of our study is to compare the current practice of 7 cm H₂O to using higher pressures of 10 cm H₂O and to investigate whether the higher pressures of CPAP reduce re-intubation.

The results of this research will be used by Miss Anna Kidman to obtain a *Doctor of Philosophy* degree at the University of Melbourne.

3. What does participation in this research involve?

Your baby's participation in this study will involve the signing of witnessed, informed consent after he/she is screened for eligibility prior to him/her having their breathing tube removed.

When the doctors decide your baby is ready to try breathing by themselves, participation in the ÉCLAT study will involve your baby receiving a CPAP of 7 cm H₂O or 10 cm H₂O after his/her breathing tube is removed. Your baby will be participating in a randomised controlled research project. You will not be able to choose which CPAP level your baby will receive. To determine which level results in the better outcomes we need to compare different treatments. We put babies into groups and give each group a different treatment. The results are compared to see if one is better. To try to make sure the groups are the same, each baby is put into a group by chance (random).

Regardless of which group your baby is allocated to, they will continue to receive routine care from the doctors and nurses as they would without this trial. They will only have specific guidelines for how their breathing support will be managed.

If you choose to allow your baby to participate in the ÉCLAT study, they should not require any extra blood tests, procedures or investigations. There may be extra observations documented by medical and nursing staff however this will not disturb your baby in any way. If your baby has a change in condition the medical staff will escalate care appropriately regardless of what CPAP treatment your baby is receiving.

Your baby will remain in the study until discharge. Data will be collected from your baby's medical chart and there will be no follow up required after you are discharged from hospital.

This research project has been designed to make sure the researchers interpret the results in a fair and appropriate way and avoids investigators or participants jumping to conclusions. There are no additional costs associated with participation in this research project, nor will you or the your baby be paid. The CPAP used is currently used for all babies in this unit.

1
2
3 **4. What does your baby have to do?**

4 To participate in the ÉCLAT study you or your baby will not have to do anything different that you
5 usually would.
6

7
8 **5. Other relevant information about the research project**

9 The ÉCLAT will aim to recruit 200 babies over 2 years. Other hospitals may be invited to be
10 involved. The project involves researchers from Monash Newborn, The Royal Women's Hospital
11 and the University of Melbourne.
12

13
14 **6. Does your baby have to take part in this research project?**

15 Participation in any research project is voluntary. If you do not wish for your baby to take part, they
16 do not have to. If you decide that they can take part and later change your mind, you are free to
17 withdraw your baby from the project at any stage.
18

19 If you do decide that your baby can take part, you will be given this Participant Information and
20 Consent Form to sign and you will be given a copy to keep.
21

22
23 Your decision that your baby can or cannot take part, or that they can take part and then be
24 withdrawn, will not affect their routine treatment, relationship with those treating them, or their
25 relationship with The Site.
26

27 **7. What are the alternatives to participation?**

28 Your baby does not have to take part in this research project to receive treatment at this hospital. If
29 your baby is not in the study they will receive routine care as per normal.
30

31
32 **8. What are the possible benefits of taking part?**

33 We cannot guarantee or promise that your baby will receive any benefits from this research. The
34 results of the study will be important in helping us to look after premature babies in the future, and
35 may change the way we provide breathing support to these babies.
36

37
38 **9. What are the possible risks and disadvantages of taking part?**

39 Medical treatments can cause side effects. your baby may have none, some or all of the effects listed
40 below, and they may be mild, moderate or severe. If your baby has any of these side effects, or you
41 are worried about them, talk with your baby's bedside nurse to contact the study investigators or the
42 treating doctor. The investigator will also be looking out for side effects including; Air leak
43 syndromes causing difficulty to breath, injury to the skin/septum around the nose and the usual
44 discomfort some babies find from having prongs in their nose.
45

46
47 There may be side effects that the researchers do not expect or do not know about and that may be
48 serious. Tell the principle investigator/ study doctor/ treating team or bedside nurse immediately
49 about any new or unusual symptoms that your baby gets.
50

51 **10. What will happen to your baby's test samples?**

52 No physical data/ tissue samples will be collected for this study
53

54
55 **11. What if new information arises during this research project?**

56 Sometimes during the course of a research project, new information becomes available about the
57 treatment that is being studied. If this happens, the investigator will tell you about it and discuss with
58 you whether you want your baby to continue in the research project. If you decide to withdraw your
59
60

1
2
3 baby, clinical care as usual will continue. If you decide that your baby can continue in the research
4 project, you will be asked to sign an updated consent form.
5 Also, on receiving new information, the investigator might consider it to be in your baby best
6 interests to withdraw them from the research project. If this happens, the investigator will explain the
7 reasons and arrange for your baby regular health care to continue.
8
9

10 **12. Can your baby have other treatments during this research project?**

11 This study will not affect any other treatments/ potential treatments your baby will receive.
12

13 **13. What if I withdraw my baby from this research project?**

14 If you decide to withdraw your baby from the project, please notify a member of the research team
15 before you withdraw them. This notice will allow that person or the research supervisor to further
16 discuss any health risks or special requirements linked to withdrawing.
17

18
19 If you do withdraw your baby during the research project, the study doctor and relevant study staff
20 will not collect additional personal information, although personal information already collected will
21 be retained to ensure that the results of the research project can be measured properly and to comply
22 with law. You should be aware that data collected by the sponsor up to the time of withdrawal will
23 form part of the research project results. If you do not want them to do this, you must tell them
24 before your baby joins the research project.
25

26
27 **14. Could this research project be stopped unexpectedly?**

28 This research project may be stopped unexpectedly for a variety of reasons. These may include
29 reasons such as:

- 30
31 • Unacceptable side effects
32 • The drug/treatment/device being shown not to be effective
33 • The drug/treatment/device being shown to work and not need further testing
34 • Decisions made in the commercial interests of the sponsor or by local regulatory/health authorities.
35

36
37 **15. What happens when the research project ends?**

38 The results of this research project will be submitted for publication in a medical journal, and also
39 used as part of a thesis towards a postgraduate degree. Both of these formats are made available to
40 the public. A plain language summary of group results will also be made available to you at the end
41 of the trial if you request it.
42

43 **Part 2 How is the research project being conducted?**

44
45 **16 What will happen to information about your baby?**

46 By signing the consent form you consent to the principle investigator and relevant research staff
47 collecting and using personal information about your baby for the research project. Any information
48 obtained in connection with this research project that can identify your baby will remain confidential.
49 All data and information collected will be stored under a de-identified number only accessible by the
50 research team. The information will be kept for 25 years then destroyed. Only the research team can
51 access this data during this time.
52

53 Your baby's information will only be used for the purpose of this research project and it will only be
54 disclosed with your permission, except as required by law.
55

56
57 Information about your baby may be obtained from their health records held at this and other health
58 services, for the purpose of this research. By signing the consent form, you agree to the study team
59 accessing health records if they are relevant to your baby's participation in this research project.
60

1
2
3
4 It is anticipated that the results of this research project will be published and or presented in a variety
5 of forums. In any publication and/or presentation, information will be provided in such a way that
6 your baby cannot be identified, except with your permission. All individual results will be grouped
7 into their treatment stream, de-identified and not discussed on an individual level.
8
9

10 Information about your baby's participation in this research project will be recorded in their health
11 records.
12

13 In accordance with relevant Australian and or Victorian state privacy and other relevant laws, you
14 have the right to request access to your baby's information collected and stored by the study team.
15 You also have the right to request that any information with which you disagree be corrected. Please
16 contact the study team member named at the end of this document if you would like to access your
17 baby's information.
18
19

20 Any information obtained for the purpose of this research project that can identify the participant
21 will be treated as confidential and securely stored. It will be disclosed only with your permission, or
22 as required by law.
23
24

25 **17. Complaints and Compensation**

26 If your baby suffers any injuries or complications as a result of this research project, you should
27 contact the study team as soon as possible and you will be assisted with arranging appropriate
28 medical treatment for your baby. If your baby is eligible for Medicare, they can receive any medical
29 treatment required to treat the injury or complication, free of charge, as a public patient in any
30 Australian public hospital.
31
32

33 **18. Who is organising and funding the research?**

34 This research project is being conducted by Anna Kidman for her Doctor of Philosophy degree. No
35 member of the research team will receive a personal financial benefit from your baby's involvement
36 in this research project (other than their ordinary wages).
37
38

39 **19. Who has reviewed the research project?**

40 All research in Australia involving humans is reviewed by an independent group of people called a
41 Human Research Ethics Committee (HREC). The ethical aspects of this research project have been
42 approved by the HREC of Monash Children's Hospital/ The Site Melbourne, Australia.
43
44

45 This project will be carried out according to the *National Statement on Ethical Conduct in Human*
46 *Research (2007)*. This statement has been developed to protect the interests of people who agree to
47 participate in human research studies.
48

49 **20. Further information and who to contact**

50 The person you may need to contact will depend on the nature of your query.
51 If you want any further information concerning this project or if your baby has any medical problems
52 which may be related to their involvement in the project (for example, any side effects), you can
53 contact the principal study investigator.
54
55

56 Anna Kidman
57 Monash Newborn
58 Level 5, Monash Children's Hospital
59 246 Clayton Road

Dr Risha Bhatia
Monash Newborn
Level 5, Monash Children's Hospital
246 Clayton Road

Clayton 3168
 Phone: + 614 238 161 97
 +61 3 8572 3737

Clayton 3168
 Phone: +61 3 8572 3650

Clinical contact person

If you have any clinical concerns about your baby at any time, you can always speak to your baby's doctor or bedside nurse.

For matters relating to research at the site at which **your baby** is participating, the details of the local site complaints person are:

Complaints contact person

Name	
Position	
Telephone	
Email	

If you have any complaints about any aspect of the project, the way it is being conducted or any questions about being a research participant in general, then you may contact:

Reviewing HREC approving this research and HREC Executive Officer details

Reviewing HREC name	
HREC Executive Officer	
Telephone	
Email	

Consent Form – Parent/Guardian

Title	<i>Extubation CPAP Level Assessment Trial</i>
Short Title	<i>ÉCLAT</i>
Protocol Number	<i>1</i>
Project Sponsor	<i>Anna Kidman – PhD study</i>
Coordinating Principal Investigator/ Principal Investigator	<i>Anna Kidman & Dr Risha Bhatia (Monash Health)</i>
Associate Investigator(s)	<i>Dr Brett Manley (Royal Women’s Hospital) Dr Rose Boland (Royal Women’s Hospital) Professor Peter Davis (Royal Women’s Hospital)</i>
Location	<i>Monash Newborn</i>

Consent Agreement

I have read the Participant Information Sheet, or someone has read it to me in a language that I understand.

I understand the purposes, procedures and risks of the research described in the project.

I have had an opportunity to ask questions and I am satisfied with the answers I have received.

I freely agree to my baby participating in this research project as described and understand that I am free to withdraw them at any time during the research project without affecting their future health care.

I understand that I will be given a signed copy of this document to keep.

Declaration by Parent/Guardian – for Parent/Guardian who has read the information

Name of Baby (please _____)	
Name of Parent/Guardian (please _____)	
Signature of Parent/Guardian _____	Date _____

1
2
3 **Declaration - for Parent/Guardian unable to read the information and consent form**
4

5
6 Witness to the informed consent process

7
8 Name (please print) _____
9

10 Signature _____ Date _____
11

12
13 * Witness is not to be the investigator, a member of the study team or their delegate. In the event that
14 an interpreter is used, the interpreter may not act as a witness to the consent process. Witness must be
15 18 years or older.
16

17
18
19 **Declaration by Study Doctor/Senior Researcher[†]**
20

21
22 I have given a verbal explanation of the research project, its procedures and risks and I believe that
23 the parent/guardian has understood that explanation.
24

25
26 Name of Investigator/
27 Senior Researcher[†] (please
28 print) _____
29

30 Signature _____ Date _____
31
32

33
34 [†] A senior member of the research team must provide the explanation of, and information
35 concerning, the research project.
36

37 Note: All parties signing the consent section must date their own signature.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Form for Withdrawal of Participation – Parent/Guardian

Title	<i>Extubation CPAP Level Assessment Trial</i>
Short Title	<i>ÉCLAT</i>
Protocol Number	<i>1</i>
Project Sponsor	<i>Anna Kidman – PhD study</i>
Coordinating Principal Investigator/ Principal Investigator	<i>Anna Kidman & Dr Risha Bhatia (Monash Health)</i>
Associate Investigator(s)	<i>Dr Brett Manley (Royal Women’s Hospital) Dr Rose Boland (Royal Women’s Hospital) Professor Peter Davis (Royal Women’s Hospital)</i>
Location	<i>Monash Newborn</i>

Declaration by Parent/Guardian

I wish to withdraw my baby from participation in the above research project and understand that such withdrawal will not affect their routine treatment, relationships with those treating them or the relationship with Monash Children’s Hospital – The Site .

Name of Baby (please print)	_____
Name of Parent/Guardian (please print)	_____
Signature of Parent/Guardian	_____ Date _____

Declaration by Investigator/Senior Researcher[†]

I have given a verbal explanation of the implications of withdrawal from the research project and I believe that the parent/guardian has understood that explanation.

Name of Investigator Senior Researcher [†] (please print)	_____
Signature	_____ Date _____

[†] A senior member of the research team must provide the explanation of, and information concerning, withdrawal from the research project.

Note: All parties signing the consent section must date their own signature.

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586

		Page
	Reporting Item	Number
Administrative information		
Title	#1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	2

1	Trial registration	#2a	Trial identifier and registry name. If not yet registered,	1
2			name of intended registry	
3				
4				
5				
6	Trial registration:	#2b	All items from the World Health Organization Trial	1
7			Registration Data Set	
8	data set			
9				
10				
11				
12	Protocol version	#3	Date and version identifier	1
13				
14				
15	Funding	#4	Sources and types of financial, material, and other	11
16			support	
17				
18				
19				
20	Roles and	#5a	Names, affiliations, and roles of protocol contributors	1
21				
22	responsibilities:			
23				
24	contributorship			
25				
26				
27				
28	Roles and	#5b	Name and contact information for the trial sponsor	11
29				
30	responsibilities:			
31				
32	sponsor contact			
33				
34	information			
35				
36				
37				
38	Roles and	#5c	Role of study sponsor and funders, if any, in study	N/A
39			design; collection, management, analysis, and	
40	responsibilities:		interpretation of data; writing of the report; and the	
41			decision to submit the report for publication, including	
42	sponsor and funder		whether they will have ultimate authority over any of	
43			these activities	
44				
45				
46				
47				
48				
49				
50				
51				
52	Roles and	#5d	Composition, roles, and responsibilities of the	1,10,11
53			coordinating centre, steering committee, endpoint	
54	responsibilities:		adjudication committee, data management team, and	
55				
56	committees			
57				
58				
59				
60				

other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)

Introduction

Background and rationale	#6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	3,4
Background and rationale: choice of comparators	#6b	Explanation for choice of comparators	4
Objectives	#7	Specific objectives or hypotheses	4
Trial design	#8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	4
Methods:			
Participants, interventions, and outcomes			
Study setting	#9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	4

1	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If	5
2			applicable, eligibility criteria for study centres and	
3			individuals who will perform the interventions (eg,	
4			surgeons, psychotherapists)	
5				
6				
7				
8				
9				
10				
11	Interventions:	#11a	Interventions for each group with sufficient detail to	4,5
12			allow replication, including how and when they will be	
13	description		administered	
14				
15				
16				
17				
18				
19	Interventions:	#11b	Criteria for discontinuing or modifying allocated	6
20			interventions for a given trial participant (eg, drug dose	
21	modifications		change in response to harms, participant request, or	
22			improving / worsening disease)	
23				
24				
25				
26				
27				
28				
29	Interventions:	#11c	Strategies to improve adherence to intervention	6
30			protocols, and any procedures for monitoring adherence	
31	adherence		(eg, drug tablet return; laboratory tests)	
32				
33				
34				
35				
36	Interventions:	#11d	Relevant concomitant care and interventions that are	7
37			permitted or prohibited during the trial	
38	concomitant care			
39				
40				
41				
42	Outcomes	#12	Primary, secondary, and other outcomes, including the	7,8,9
43			specific measurement variable (eg, systolic blood	
44			pressure), analysis metric (eg, change from baseline,	
45			final value, time to event), method of aggregation (eg,	
46			median, proportion), and time point for each outcome.	
47				
48				
49				
50				
51				
52				
53			Explanation of the clinical relevance of chosen efficacy	
54			and harm outcomes is strongly recommended	
55				
56				
57				
58				
59				
60				

1	Participant timeline	#13	Time schedule of enrolment, interventions (including	6
2			any run-ins and washouts), assessments, and visits for	
3			participants. A schematic diagram is highly	
4			recommended (see Figure)	
5				
6				
7				
8				
9				
10				
11	Sample size	#14	Estimated number of participants needed to achieve	4
12			study objectives and how it was determined, including	
13			clinical and statistical assumptions supporting any	
14			sample size calculations	
15				
16				
17				
18				
19				
20				
21	Recruitment	#15	Strategies for achieving adequate participant enrolment	4
22			to reach target sample size	
23				
24				
25				
26	Methods:			
27				
28	Assignment of			
29	interventions (for			
30	controlled trials)			
31				
32				
33				
34				
35				
36	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	5
37	generation		computer-generated random numbers), and list of any	
38			factors for stratification. To reduce predictability of a	
39			random sequence, details of any planned restriction (eg,	
40			blocking) should be provided in a separate document	
41			that is unavailable to those who enrol participants or	
42			assign interventions	
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53	Allocation	#16b	Mechanism of implementing the allocation sequence	5
54	concealment		(eg, central telephone; sequentially numbered, opaque,	
55				
56				
57				
58	mechanism			

1		sealed envelopes), describing any steps to conceal the	
2		sequence until interventions are assigned	
3			
4			
5			
6	Allocation:	#16c Who will generate the allocation sequence, who will	5
7			
8	implementation	enrol participants, and who will assign participants to	
9		interventions	
10			
11			
12			
13	Blinding (masking)	#17a Who will be blinded after assignment to interventions	N/A
14		(eg, trial participants, care providers, outcome	
15		assessors, data analysts), and how	
16			
17			
18			
19			
20			
21	Blinding (masking):	#17b If blinded, circumstances under which unblinding is	N/A
22		permissible, and procedure for revealing a participant's	
23	emergency	allocated intervention during the trial	
24			
25	unblinding		
26			
27			
28			
29	Methods: Data		
30			
31	collection,		
32			
33	management, and		
34			
35	analysis		
36			
37			
38			
39	Data collection plan	#18a Plans for assessment and collection of outcome,	9
40		baseline, and other trial data, including any related	
41		processes to promote data quality (eg, duplicate	
42		measurements, training of assessors) and a description	
43		of study instruments (eg, questionnaires, laboratory	
44		tests) along with their reliability and validity, if known.	
45			
46		Reference to where data collection forms can be found,	
47			
48		if not in the protocol	
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			

1	Data collection plan:	#18b	Plans to promote participant retention and complete	N/A no
2				
3	retention		follow-up, including list of any outcome data to be	long term
4			collected for participants who discontinue or deviate	follow-up
5			from intervention protocols	
6				
7				
8				
9				
10				
11	Data management	#19	Plans for data entry, coding, security, and storage,	5
12			including any related processes to promote data quality	
13			(eg, double data entry; range checks for data values).	
14			Reference to where details of data management	
15			procedures can be found, if not in the protocol	
16				
17				
18				
19				
20				
21				
22				
23	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	4
24			outcomes. Reference to where other details of the	
25			statistical analysis plan can be found, if not in the	
26			protocol	
27				
28				
29				
30				
31				
32				
33	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	4
34	analyses		adjusted analyses)	
35				
36				
37				
38				
39	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	4
40	population and		adherence (eg, as randomised analysis), and any	
41	missing data		statistical methods to handle missing data (eg, multiple	
42			imputation)	
43				
44				
45				
46				
47				
48	Methods: Monitoring			
49				
50				
51	Data monitoring:	#21a	Composition of data monitoring committee (DMC);	10
52	formal committee		summary of its role and reporting structure; statement of	
53			whether it is independent from the sponsor and	
54				
55				
56				
57				
58				
59				
60				

competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed

1			
2			
3			
4			
5			
6			
7			
8			
9			
10	Data monitoring:	#21b	Description of any interim analyses and stopping
11			
12	interim analysis		guidelines, including who will have access to these
13			
14			interim results and make the final decision to terminate
15			the trial
16			
17			
18			
19			
20	Harms	#22	Plans for collecting, assessing, reporting, and managing
21			solicited and spontaneously reported adverse events
22			
23			and other unintended effects of trial interventions or trial
24			conduct
25			
26			
27			
28			
29			
30	Auditing	#23	Frequency and procedures for auditing trial conduct, if
31			any, and whether the process will be independent from
32			investigators and the sponsor
33			
34			
35			
36			
37			
38	Ethics and		
39			
40	dissemination		
41			
42			
43	Research ethics	#24	Plans for seeking research ethics committee /
44			
45	approval		institutional review board (REC / IRB) approval
46			
47			
48	Protocol	#25	Plans for communicating important protocol
49			
50	amendments		modifications (eg, changes to eligibility criteria,
51			outcomes, analyses) to relevant parties (eg,
52			investigators, REC / IRBs, trial participants, trial
53			registries, journals, regulators)
54			
55			
56			
57			
58			
59			
60			

1	Consent or assent	#26a	Who will obtain informed consent or assent from	7,8
2			potential trial participants or authorised surrogates, and	
3			how (see Item 32)	
4				
5				
6				
7				
8				
9	Consent or assent:	#26b	Additional consent provisions for collection and use of	N/A
10	ancillary studies		participant data and biological specimens in ancillary	
11			studies, if applicable	
12				
13				
14				
15				
16	Confidentiality	#27	How personal information about potential and enrolled	10
17			participants will be collected, shared, and maintained in	
18			order to protect confidentiality before, during, and after	
19			the trial	
20				
21				
22				
23				
24				
25				
26	Declaration of	#28	Financial and other competing interests for principal	11
27	interests		investigators for the overall trial and each study site	
28				
29				
30				
31				
32	Data access	#29	Statement of who will have access to the final trial	9
33			dataset, and disclosure of contractual agreements that	
34			limit such access for investigators	
35				
36				
37				
38				
39	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care, and	N/A
40	trial care		for compensation to those who suffer harm from trial	
41			participation	
42				
43				
44				
45				
46				
47	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate trial	2
48	trial results		results to participants, healthcare professionals, the	
49			public, and other relevant groups (eg, via publication,	
50			reporting in results databases, or other data sharing	
51			arrangements), including any publication restrictions	
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Dissemination policy: #31b	Authorship eligibility guidelines and any intended use of	2
2			
3	authorship	professional writers	
4			
5			
6	Dissemination policy: #31c	Plans, if any, for granting public access to the full	N/A
7			
8	reproducible	protocol, participant-level dataset, and statistical code	
9			
10	research		
11			
12			
13			
14	Appendices		
15			
16			
17	Informed consent	#32 Model consent form and other related documentation	15
18			
19	materials	given to participants and authorised surrogates	
20			
21			
22			
23	Biological specimens	#33 Plans for collection, laboratory evaluation, and storage	N/A
24			
25		of biological specimens for genetic or molecular analysis	
26			
27		in the current trial and for future use in ancillary studies,	
28			
29		if applicable	
30			
31			

Notes:

- 18b: N/A no long term follow-up The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND 3.0. This checklist was completed on 03. February 2021 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)